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Abstract
Clinical Treatment Human Disease Networks and Comparative Effectiveness Research: Analyses
of the Medicare Administrative Data
Hao Mei
2021
As the nation’s largest healthcare payer, the Medicare program generates an unimaginable vast
volume of medical data. With an increasing emphasis on evidence-based care, how to effectively
handle and make inferences from the heterogeneous and noisy healthcare data remains an impor-
tant question. High-quality analysis could improve the quality, planning, and administrations of
health services, evaluate comparative therapies, and forward research on epidemiology and disease
etiology. This is especially true for older adults since this population’s health condition is generally
complicated with multimorbidity, and the healthcare system for older adults is riddled with admin-
istrative and regulatory complexities. Taking advantage of the scaled and comprehensive Medicare
data, this dissertation focuses on outcome research, human disease networks, and comparative
effectiveness research for older adults.
Healthcare outcome measures such as mortality, readmission, length of stay (LOS), and medi-
cal costs have been extensively studied. However, existing analysis generally focuses on one single
disease (or at most a few pre-selected and closely related diseases) or all diseases combined. It is
increasingly evident that human diseases are interconnected with each other. Motivated by the
emerging human disease network (HDN) analysis, we conduct network analysis of disease intercon-
nections on healthcare outcomes measures.
First, we propose a clinical treatment HDN that analyzes inpatient LOS data. In the network
graph, one node represents one disease, and two nodes are linked with an edge if their disease-specific
LOS are correlated (conditional on LOS of all other diseases). To accommodate zero-inflated LOS
data, we propose a network construction approach based on the multivariate Hurdle model. We
analyze the Medicare inpatient data for the period of January 2008 to December 2018. Based on
the constructed network, key network properties such as connectivity, module/hub, and temporal
variation are analyzed. The results are found to be biomedically sensible, especially from a treat-
ment perspective. A closer examination also reveals novel findings that are less/not investigated in
the individual-disease studies. This work has been published in Statistics in Medicine.
Second, considering that many healthcare outcomes are closely related to each other, we propose
a high-dimensional clinical treatment HDN that can incorporate multiple outcomes. We construct
a clinical treatment HDN on LOS and readmission and note that the proposed method can be easily
generalized to other outcomes of different data types. To deal with uniquely challenging data distri-
butions (high-dimensionality and zero-inflation), a new network construction approach is developed
based on the integrative analysis of generalized linear models. Data analysis is conducted using the
Medicare inpatient data from January 2010 to December 2018. Network structure and properties
are found to be similar to that of the LOS HDN (in Chapter 2) but provide additional insights into
disease interconnections considering both LOS and readmission. The proposed clinical treatment
of HDNs can promote a better understanding of human diseases and their interconnections, guide a
more efficient disease management and healthcare resources allocation, and foster complex network
analysis. The manuscript of this work has been drafted and is ready for submission.
Comparative effectiveness research aims to directly compare the outcomes of two or more health-
care strategies to address a particular medical condition. Such analysis can provide information
about the risks, benefits, and costs of different treatment options, thus guide better clinical de-
cisions. While conducting a randomized controlled trial is the gold-standard approach, there are
several limitations. Efforts have been made to utilize healthcare record data in comparative effec-
tiveness research. To estimate and compare causal effects of treatments/interventions, we use the
Medicare data to emulate target clinical trials and develop a deep learning-based analysis approach.
Under emulation, target clinical trials are explicitly “assembled” using the Medicare data. As
such, statistical methods for clinical trials can be directly applied to estimate causal effects. With
emulation analysis, we evaluate the effectiveness and safety outcomes of rivaroxaban versus dabiga-
tran for Medicare patients with atrial fibrillation. The results show that dabigatran is superior in
terms of time to any primary event (including ischemic stroke, other thromboembolic events, ma-
jor bleeding, and death), major bleeding, and mortality. This work has been submitted to Clinical
Epidemiology. Considering that many regression-based statistical methods (e.g., Cox proportional
hazards model for survival data) have too strict data assumptions, we further develop an innovative
deep learning-based analysis strategy. With the “emulation + deep learning” approach, we study
the survival outcomes of endovascular repair versus open aortic repair for Medicare patients with
abdominal aortic aneurysms. It is found that endovascular repair has survival advantages in both
short- and long-term mortality. This work has been published in Entropy.
Significantly different and advancing from the existing literature, this dissertation extends the
scope of outcome research, human disease networks, and comparative effectiveness research. The
findings in this dissertation are shown to have scientific merits, and the methodological develop-
ments may have other applications and serve as prototypes for future analysis.
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There is a growing consciousness among healthcare institutions for adopting the electronic health
record (EHR) system to improve care quality through evidence-based practices. As of 2015, more
than 84% of the U.S. non-federal acute care hospitals have adopted a basic EHR system [1], which
has generated an unimaginably vast volume of patient data. As healthcare data becomes more
voluminous and convoluted, there exist both opportunities and challenges. Advancements in the
statistical field to effectively handle and make inferences from the heterogeneous and noisy health-
care data are required for the transition from information to knowledge. As administrative and
billing data is one essential component of the EHR system, this dissertation focuses on the Medicare
database, aiming to answer critical biomedical questions that have been previously unanswered.
Medicare is a federal health insurance program for adults aged 65 years and above, certain
younger people with disabilities, and people with end-stage renal disease (permanent kidney failure
requiring dialysis or a transplant). As the single largest payer of healthcare in the U.S., it covers 98%
of adults aged 65 and above [2]. It also accounts for over 99% of death for the elderly population and
about 40% of all inpatient discharges [2,3]. The Centers for Medicare & Medicaid Services (CMS)
offers a wide range of datasets that follow Medicare beneficiaries across multiple care settings.
Specifically, it collects over two billion data points per year through reimbursement to hospital care
(Medicare PartA), physician and outpatient services (Medicare Part B), drug prescription (Medicare
PartD), and other health care claims. It also collects billions of other data points through enrollment
information, beneficiary eligibility checks, quality metrics, and calls to 1-800-MEDICARE [4], which
can fulfill many research purposes. In addition to its universal coverage and rich information
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contained, the Medicare data is generally of high quality since it is the basis of determination of
reimbursing eligibility. Demographic information is mostly reliable and valid because it comes from
the Social Security Administration [3]. In the literature, there have been enormous efforts exploring
the Medicare database to answer various questions. This dissertation focuses mainly on outcome
research, disease interconnections, and comparative effectiveness research.
1.1 Literature review
1.1.1 Outcome research
Healthcare outcome measures such as mortality, readmission, length of stay (LOS), and medical
costs are the quality and cost targets healthcare organizations are trying to improve. The impor-
tance of delivering high-value care for patients is increasingly emphasized, with value defined as
the health outcomes achieved per dollar spent [5]. For most if not all diseases, hundreds of these
outcomes have been extensively studied and reported to stakeholders at all levels. Such analysis
can inform a more efficient allocation of resources, identify variations of care, and reveal areas
in which interventions could improve care. The Institute for Healthcare Improvement describes
outcome measurement as “a critical part of testing and implementing changes. Measuring tells a
team whether the changes they are making lead to improvement [6].” In other words, outcome
research fosters improvement and adoption of better practices, thus further improves outcomes.
For example, Piedmont Healthcare’s evidence-based care standardization for pneumonia patients
resulted in a 56.5% relative reduction in mortality rate and a 9.3% relative reduction in LOS [7].
By improving the analytic platform and advancing its applications, the University of Texas Medical
Branch achieved a 14.5% relative decrease in their 30-day all-cause readmission rate, resulting in
$1.9 million in cost reduction [8]. Also, since outcomes informatively reflect intrinsic disease prop-
erties (prevalence, severity, trend, etc.), outcome analysis can advance disease etiology research [9].
Accordingly, understanding outcomes is essential in providing patient-centered and value-based
healthcare services. This statement is especially true for older adults since the health condition for
this population is generally complicated with multimorbidity, and the healthcare system for this
population is riddled with administrative and regulatory complexities [10].
In the literature, extensive analyses on healthcare outcomes have been done using healthcare
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record data, especially the Medicare data. They generally fall into two families. The first family
focuses on a single disease. For example, with a Saskatchewan Ministry of Health hospital adminis-
trative database, Feng and Li [11] analyzed the LOS of ischaemic heart disease. The zero-inflation
nature of data was observed, which is typical in outcome data. For most conditions, only a pro-
portion of the general population may be susceptible and have treatment [11]. Chronic diseases
not needing any hospital treatment is another contributing factor [12]. Feng and Li [11] conducted
a two-part regression analysis to accommodate zero-inflation and identified aboriginal status, age,
and gender as risk factors. Gupta et al. [13] evaluated the effect on a federal program’s outcomes
to reduce condition-specific readmission rates for the Medicare population. With interrupted time-
series and survival analyses, Gupta et al. [13] identified a reduction in readmission rate and an
increase in mortality associated with implementing the program for Medicare patients hospitalized
with heart failure. Other studies include Rinne et al. [14], who investigated the association between
LOS and readmission for chronic obstructive pulmonary disease (COPD); and Petersen et al. [15],
who compared multiple outcomes of myocardial infarction in Veterans Health Administration pa-
tients versus Medicare patients.
The second family focuses on a general population and studies all diseases combined. For
example, Huling et al. [16] proposed a framework for estimating individualized treatment rules
(ITRs) that optimize all disease combined medical costs in the Medicare population. Observing the
zero-inflation nature of the medical costs data, Huling et al. [16] employed a two-part semicontinuous
modeling, wherein the ITR is estimated by separately targeting the zero part of the outcome and
the strictly positive part. Also, they employed a cooperative LASSO penalty to simultaneously
select variables and encourage the signs of coefficients for each variable to agree between the two
components of the ITR. In healthcare outcome studies, penalized optimization is commonly used
since modeling often involves a large number of covariates, and many of them are naturally grouped
with variables in the same group being systematically related or statistically correlated. In analyzing
all diseases combined number of doctor visits data, Chatterjee et al. [17] also noted the zero-inflation
nature of data and group-wise correlation in covariates. Under such settings, they propose a unified
algorithm (Gooogle: Group Regularization for Zero-inflated Count Regression Models) using a
least-squares approximation of the mixture likelihood and a variety of group-wise penalties on the
coefficients. Other examples of all diseases combined outcome studies include Jung et al. [18], who
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compared general readmission rates in two populations: Medicare Advantage and Medicare Fee-
For-Service; and Dall et al. [19], who examined the increasing trend of healthcare resource demand
and identified the overall shortage of hospital beds in the U.S.
There are also a few “scattered” studies analyzing treatment measures of a few pre-selected and
closely related diseases, such as cardiovascular diseases [20] and certain cancers [21]. Correlations
between outcomes of different diseases have been noted in such studies. For example, in a study
investigating LOS variations within the Diagnosis Related Groups, Berki et al. [22] argued that
patients with similar diagnostic and other case-management-relevant characteristics had correlated
LOS measures and emphasized the necessity of jointly analyzing LOS behaviors for diseases homo-
geneous in clinically relevant characteristics. In a study examining the association between COPD
readmission and other quality measures, Rinne et al. [23] discovered modest correlations between
COPD readmission rate and readmission rates for other medical conditions, including heart failure,
acute myocardial infarction, pneumonia, and stroke; low correlations between COPD readmission
rate and mortality rates for all measured conditions; and significant correlations between COPD
readmission rate and all patient experience measures. The authors suggested that although pay-
for-performance programs generally focused on individual disease outcomes, there may be common
organizational factors that influenced multiple disease-specific outcomes. Similar arguments have
been made in follow-up studies. However, existing studies on outcome interconnections are limited
to a small number of diseases.
1.1.2 Human disease network
There is increasing evidence that human diseases are not isolated from each other. Instead, dis-
eases are related through multiple dimensions. For example, correlation between diseases can be
caused by 1) shared or causal disease etiology (e.g., between breast cancer, ovarian cancer, and
other hormone-related diseases; between diabetes and its complications), 2) shared environmen-
tal, dietary, socioeconomic, and other risk factors (e.g., between multiple respiratory diseases that
share air pollution as a common risk factor), and 3) shared prevention, diagnosis, and treatment
strategies (e.g., between diseases that need radiological treatments). The emerging human disease
network (HDN) analysis in the past two decades offers a platform to explore disease interconnec-
tions using a single graph-theoretic framework. In an HDN, one node represents one disease, and
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two nodes are connected with an edge if they are determined to be associated or correlated by
an underlying model. Disease interconnection studies, especially the HDN ones, have significantly
advanced biomedical research beyond the individual-disease ones.
Goh et al. [24] were the first to develop the concept of HDN and establish pan-disease in-
terconnections. They proposed an HDN that linked disorders and disease genes by the known
disorder–gene associations, indicating many diseases’ common genetic origin. The authors found
that, while a few essential human genes play a central role in the human interactome, the vast ma-
jority of disease genes are nonessential, show no tendency to encode hub proteins, and are localized
in the functional periphery of the network. A closer examination showed that the network struc-
ture supported distinct disease-specific functional modules. This study and a few other follow-up
HDNs are gene-centric, under which two diseases are interconnected if they share common genetic
risk factors. For example, Lee et al. [25] built a network that linked two diseases if the mutated
enzymes associated with them catalyzed adjacent metabolic reactions. They found that connected
disease pairs displayed higher correlated reaction flux rate, corresponding enzyme-encoding gene
coexpression, and higher comorbidity than those with no metabolic link between them. Li and
Agarwal [26] constructed an HDN by linking diseases based on shared pathways where disease-
associated genes are enriched. Examining the network properties, the authors provided examples
of novel disease relationships that cannot be readily captured through simple literature search or
gene overlap analysis. Such HDNs representing various molecular relationships have provided new
insights into disease etiology, classification, and shared biological mechanisms.
Noting that genetic information reflects only part of disease interconnections, efforts have been
made to utilize the healthcare record data in constructing HDNs. Working on the clinical history of
30 million patients, Hidalgo et al. [27] developed the first phenotypic disease network that connects
two diseases if their phenotypes are correlated (e.g., comorbidity). This kind of phenotypic HDN
has important clinical implications, as the network structure is closely relevant to understanding
illness progression. Hidalgo et al. showed that 1) diseases progressed preferentially along with
the links of the network; 2) this progression is different for patients with different genders and
racial backgrounds, and 3) patients affected by highly connected diseases had a higher mortality
risk. Follow-up studies along this direction include Jiang et al. [28], who explored the Taiwan
National Health Insurance Research Database and calculated disease comorbidity probability using
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the φ-correlation; and Roque et al. [29], who used text mining and data extraction techniques on
unstructured electronic health record data. Phenotypic HDNs utilize largely accessible healthcare
administrative data, have lucid interpretability, and complement existing genetic HDNs by accom-
modating non-molecular connections. There are also studies that go multi-layer, under which one
layer describes the genetic interconnections among diseases, and another layer describes the phe-
notypic interconnections. Building a multi-layer HDN, Halu et al. [30] showed that diseases with
common genetic constituents tended to share symptoms and uncovered how phenotype information
helped boost genotype information.
There emerges a relatively new family of HDN that examines disease interconnections in health-
care outcomes. Ma et al. [31] were the first to construct a clinical treatment HDN by analyzing
medical costs data in the Taiwan National Health Insurance Research Database. They used a
two-part model for the marginal distribution of disease-specific medical costs and a copula-based
approach to identify unconditional pairwise interconnection between medical costs of two diseases.
With medical costs informatively reflect the financial burden of care and disease severity, such a
clinical treatment HDN has unique implications for disease management and resource allocation.
Healthcare outcome measures are “correlated with” but not equivalent to genetic risk factors and
phenotypes. The interconnections in disease-associated outcomes cannot be derived directly from
the existing genetic and phenotypic HDNs. In other words, a clinical treatment HDN captures dis-
ease interconnections from not only shared causal disease etiology, shared environmental, dietary,
and socioeconomic risk factors, but also shared prevention, diagnosis, and treatment strategies.
1.1.3 Comparative effectiveness research
Comparative effectiveness research aims to evaluate and compare the outcomes of two or more
healthcare strategies to address a particular medical condition. The goal of comparative effective-
ness research is to provide more evidence to guide clinical decisions. Ideally, this should be achieved
through the gold standard double-blinded randomized clinical trials. However, there exist several
practical limitations. A randomized clinical trial is generally expensive and sometimes infeasible.
Limited sample size and inadequate follow-ups are common scenarios that diminish the statistical
power of a randomized controlled trial. Moreover, a randomized controlled trial tests treatment
efficacy under rigorous experimental conditions rather than real-world effectiveness. Results from
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a randomized clinical trial may have limited generalizability to other than designed populations
(e.g., older adults who are underrepresented in clinical trials).
With the concerns mentioned above, efforts have been made to focus on observational data in de-
veloping comparative effectiveness evidence. As one of the richest sources of treatment information
in the country, the Medicare data plays an essential role in observational comparative effective-
ness research. For example, Graham et al. [32] examined the effectiveness and safety outcomes of
dabigatran versus warfarin for Medicare patients with nonvalvular atrial fibrillation. They found
that dabigatran was associated with a reduced risk of ischemic stroke, intracranial hemorrhage,
death, and increased risk of major gastrointestinal bleeding. The authors used propensity scores to
match the two treatment arms and Cox proportional hazards regression to compare time to events.
Even with randomization in clinical trials, propensity scores are generally used to weigh or match
cohorts to account for potential confounding in comparative effectiveness research. In a study of
survival outcomes after endovascular repair versus open repair of abdominal aortic aneurysm in
Medicare beneficiaries, Schermerhorn et al. [33] also analyzed propensity score-matched cohorts
with Cox proportional hazards regression. They found that endovascular repair was associated
with a substantial early survival advantage that gradually decreased over time.
Observational comparative effectiveness studies using healthcare records data are more cost-
effective, have a large sample size and statistical power, and implicate actual practices by assessing
real-world effectiveness. However, it is well established that observational studies generate results
on associations instead of the desired causality. To tackle this problem, statistical techniques
have been developed to conduce causal inferences using observational data. For example, van der
Laan and Rubin [34] proposed the targeted maximum likelihood estimation (TMLE), which is an
automated and iterative procedure to analyze censored observational data in a way that allows
effect estimation in the presence of confounding factors. Chipman et al. [35] proposed a Bayesian
additive regression trees (BART) model where each tree is constrained by a regularization prior,
and fitting and inference are accomplished via an iterative Bayesian backfitting MCMC algorithm
that generates samples from a posterior. Effectively, BART is a nonparametric Bayesian regression
approach that enables full posterior inference on average causal effects. As the existing literature on
this topic is vast, we note that different methods have different advantages and disadvantages [36].
There exists no dominating approach.
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In this dissertation, we focus on the emulation approach proposed by Hernan et al. [37]. Under
emulation, target clinical trials are explicitly “assembled” using observational data, and statistical
techniques for randomized clinical trials can be directly applied. As such, compared to causal in-
ference techniques such as the TMLE and BART, emulation has much more lucid interpretations.
Using EHR data, especially the Medicare data, this approach has been employed on various illness
conditions and treatment strategies. Petito et al. [38] evaluated the suitability of emulation analysis
for assessing the effectiveness of adding a drug (fluorouracil or erlotinib) to an existing treatment
regimen on the overall survival of elderly patients with cancer. They utilized the Surveillance,
Epidemiology, and End Results (SEER)–Medicare linked database to emulate two existing clini-
cal trials. The emulation analysis findings were not meaningfully different from those in elderly
subgroup analyses reported from randomized trials. However, naive observational estimates were
not compatible with those from previous trials. In the situation that a real randomized trial is
not practical, Garćıa-Albéniz et al. [39] utilized the Medicare data to emulate a hypothesized trial
that evaluates the effectiveness and safety of screening colonoscopy prevent colorectal cancer. They
concluded a modest benefit of screening colonoscopy in preventing colorectal cancer for beneficiaries
aged 70 to 74 years and a smaller benefit for older beneficiaries.
1.2 Background studies
In addition to a throughout literature review, I have collaborated with interdisciplinary researchers
at Yale Center for Outcome Research and Evaluation on a variety of outcomes studies, mostly
involving analyses of the Medicare/Medicaid administrative data. These studies are limited to
disease-specific or all diseases combined outcome analysis, which have ignored the complex disease
interconnection. However, they demonstrate the significance of outcome research and are essential
motivations of this dissertation.
In a series of three papers investigating emergency department (ED) utilization in the Medicare
population, Venkatesh et al. first constructed an operational definition for ED visitation using
comprehensive Medicare data sets [40], then examined ED utilization in vulnerable older adult sub-
populations [41, 42]. Despite the high profile of ED visits in analyses using administrative claims,
little work had evaluated the degree to which existing definitions based on claims data accurately
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capture conventionally defined hospital-based ED services. Based on expert consensus and clinician
review, we applied several modifications to existing definitions to construct a new operational
definition for ED visits using both provider- and facility-based Medicare administrative claims. A
comparison between our definition and three existing definitions showed significant differences in
ED visitation estimates, as our definition identified ED visits not captured by previous definitions.
This work has provided several points of guidance to researchers seeking to use administrative
claims data for ED research. Based on the newly developed definition, we further investigated ED
utilization in the vulnerable sub-populations, including Medicare beneficiaries with multiple chronic
conditions (MCCs), dual eligibility, hospice enrollment, and skilled nursing facility (SNF) residence.
We found that vulnerable sub-populations disproportionately visit the ED compared to physician
offices for unscheduled care. For example, 1) dual-eligible beneficiaries demonstrated higher ED
visit rates and lower office visit rates for unscheduled care; 2) the sub-population with MCCs uses
both the ED and the office settings for unscheduled care more so than any other groups, and 3)
a higher proportion of unscheduled care were made to EDs by beneficiaries after a SNF stay in
comparison to those actively residing in a SNF and those without SNF utilization. These findings
have important implications for improving care coordination, measuring quality, or reform payment
to influence ED visitation.
Another work involving ED visits evaluated the effectiveness of an ED-initiated Patient Navi-
gation program (ED-PN) in improving health care access for Medicaid beneficiaries [43]. Medicaid
enrollees frequently utilized the ED due to barriers to access health care services in other settings.
The ED-PN program was designed to have patient navigators who met with the ED patients and
linked them to financial assistance programs and other resources. They helped patients identify a
primary care provider, assisted them in scheduling primary care and specialist appointments, and
accompanied them for up to three visits. They also educated patients on why they shouldn’t use
the ED for primary care and taught them how to navigate the healthcare system. To evaluate the
ED-PN program’s effectiveness, we conducted a prospective, randomized controlled trial comparing
ED-PN with usual care among 100 Medicaid-enrolled frequent ED users (defined as 4–18 ED visits
in the prior year). The primary outcome was ED utilization during the 12 months pre and post-
enrollment. Secondary outcomes included hospitalizations, outpatient utilization, hospital costs,
and Medicaid costs. Using the difference-in-difference approach, we found that the ED-PN pro-
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gram demonstrated significant reductions in ED visits and hospitalizations in the 12 months after
enrollment. We also compared characteristics between ED-PN patients with and without reduced
ED utilization and found that older patients and patients with lower health literacy reduced uti-
lization more than younger patients and patients with higher health literacy. This study provides
high-quality evidence to support ED-PN’s effectiveness, which has important clinical implications
for improving care for the high-need and high-cost Medicaid patients.
Collaborative analyses have also been done on other outcome measures. Considering that the
accrual of final Medicare claims can take up to a year, Li et al. [44] developed real-time reporting
(within two months from admission) models for national trends of multiple outcomes. Specifically,
with incomplete and non-final claims data, we developed time series models for real-time estimation
of national admission, readmission, and observation-stay rates in Medicare patients with acute
myocardial infarction, heart failure, or pneumonia. It was shown that these models provided
validated estimates and predictions. This work allows policymakers to track policy decisions’ impact
in real-time and enable hospitals to better monitor their performance compared to a national
benchmark. In response to the tremendous impact of coronavirus disease 2019 (COVID-19), Janke
et al. [45] examined the relationship between hospital resources and mortality among hospital
referral regions from March 1 to July 26, 2020. Using American Hospital Association data and
COVID-19 data from the New York Times, we found that geographic areas with fewer intensive
care unit beds, nurses, and general medicine/surgical beds were significantly associated with more
deaths. The association was found stronger in the early pandemic period. Our findings underscore
the potential impact of innovative hospital capacity protocols and care models to create resource
flexibility and limit system overload early in a pandemic.
1.3 Summary
Through a comprehensive literature review and a variety of collaborative studies, the importance of
healthcare outcome analysis has been well established. However, it is noted that existing analyses
are generally limited to a single disease (or at most a few pre-selected and closely related diseases)
or all diseases combined. The complex interconnections in human diseases have been ignored. Mo-
tivated by the emerging of HDN analysis, the first two aims (Chapter 2 and Chapter 3) of this
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dissertation are to investigate interconnections in healthcare outcome measures at a pan-disease
level. Specifically, in Chapter 2, we construct a clinical treatment HDN on Medicare LOS data. To
accommodate zero-inflated data, we develop a network construction approach based on the multi-
variate Hurdle approach. In Chapter 3, considering many outcomes are closely related to each other,
we expand the clinical treatment HDN to incorporate multiple outcomes: LOS and readmission.
We propose an innovative modeling approach based on integrative analysis of generalized linear
models to accommodate high-dimensionality and zero-inflation. In both chapters, novel modeling
and estimation approaches are developed to accommodate uniquely challenging data distributions.
In addition, while most existing HDNs are based unconditional pairwise relationships, our models
quantify conditional disease interconnections, which are more informative and statistically more
challenging. Based on the constructed networks, fundamental network properties such as connec-
tivity, module/hub, and temporal trend are examined to answer important biomedical questions.
The proposed clinical treatment HDNs can promote a better understanding of human diseases
and their interconnections, guide a more efficient disease management and healthcare resources
allocation, and foster complex network analysis.
It is also noted that comparative effectiveness research analyzing the observational Medicare
data can only lead to conclusions on association instead of causation. Causal inference is often
desired to make definite conclusions on the relative performance of treatment strategies. Ideally,
this should be achieved using randomized controlled trials, as we have done in evaluating the effects
of the ED-PN program on ED utilization and other outcomes [43]. However, as discussed earlier,
a randomized controlled trial is not always feasible and has limitations. To take advantage of the
scaled Medicare data, Chapter 4 aims to conduct causal inference with the emulation approach.
Under emulation, we use the observational Medicare data to explicitly “assemble” a hypothetical
clinical trial with rigorously defined inclusion/exclusion criteria, treatment regimens, and analysis
procedures. Statistical methods for clinical trials can be directly applied, and causal conclusions
can thus be drawn. We first conduct a case study to evaluate the effectiveness and safety outcomes
of rivaroxaban versus dabigatran for Medicare patients with atrial fibrillation. We analyze the
Medicare data using propensity score and inverse probability of treatment (IPT) weighting Cox
proportional hazards regression, which are commonly used statistical techniques in clinical trials.
Considering that the Cox proportional hazards model has too strict data assumptions, we further
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develop a deep learning-based analysis strategy with relaxed assumptions for survival data. This
work is the first to introduce deep learning to the emulation paradigm. Building on the existing deep
learning components, we propose an innovative analysis pipeline that mimics the “propensity score
+ IPT weighting Cox regression” approach and conduct a bootstrap-type procedure for variation
assessment. With the proposed “emulation + deep learning” approach, we conduct another case
study to compare survival outcomes of endovascular repair versus open aortic repair for Medicare
patients with abdominal aortic aneurysms.
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Chapter 2
Clinical Treatment Human Disease
Network: Analysis of the Medicare
Inpatient Length of Stay Data
2.1 Introduction
For most if not all diseases, clinical treatment measures, such as inpatient LOS, number of out-
patient treatments, and inpatient/outpatient treatment cost, have been extensively studied. Such
analysis has important implications for stakeholders at all levels. For example, the analysis of
LOS can inform hospitals how to effectively and efficiently allocate beds and human resources and
plan forward [46]. The analysis of treatment cost can inform government agencies and individ-
uals/households how to allocate financial resources as well as guide insurance agencies on more
accurately determining premium [19]. Clinical treatment measures can also informatively reflect
prevalence, trend, severity, and other disease properties, and as such, the analysis can also advance
research on disease etiology [9].
In this article, we focus on LOS because of its high clinical relevance and note that other clinical
treatment measures can be analyzed in a similar manner. LOS is one of the most watched clinical
treatment measures. In the U.S., hospital stays cost the health system at least $377.5 billion per
year [19]. There have been extensive clinical and managerial efforts that target LOS as an indicator
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of high-value care [46]. Researchers have also established significant positive correlations between
LOS and disease severity. For example, according to Hicks et al. [47], using the Medis Groups
which allocates patients into five admission severity groups, there is an increase in mean LOS from
2.7 days to 14.3 days from the lowest to the highest severity group.
Existing studies on LOS and other clinical treatment measures mostly belong to two families.
The first family analyzes the treatment of a single disease. For example, with a Saskatchewan
Ministry of Health hospital discharge administrative database, Feng and Li [11] analyzed the LOS
of ischaemic heart disease. The zero-inflation nature of data was observed, which is common as for
most diseases, only a proportion of the general population may be susceptible and have treatment.
Chronic diseases not needing any hospital treatment is another contributing factor [11, 12]. Feng
and Li [11] conducted a two-part regression analysis to accommodate zero-inflation and identified
aboriginal status, age, and gender as risk factors. The second family of analysis considers diseases all
together. For example, studies have examined the increasing trend of healthcare resource demand
and identified the overall shortage of hospital beds in the U.S. and other countries [19]. There
are also a few “scattered” studies analyzing treatment measures of a few pre-selected and closely
related diseases, such as cardiovascular diseases [20] and certain cancers [21].
Significantly different and advancing from the existing literature, in this article, we will study
the interconnections in LOS among diseases. This has been partly motivated by the surge of disease
interconnection studies in the past two decades. For example, Goh et al. [24] was the first to develop
the concept of human disease network (HDN) and establish pan-disease interconnections. This and
a few other followup HDNs [26, 48] are gene-centric, under which two diseases are interconnected
if they share common genetic risk factors. Building on the clinical history of 30 million patients,
Hidalgo et al. [27] developed the first phenotypic disease network. Followup studies include Jiang
et al. [28], Roque et al. [29], and others. Under such a network, two diseases are interconnected
if their phenotypes/outcomes are correlated (e.g., comorbidity). There are also studies that go
multi-layer [30], under which one layer describes the genetic interconnections among diseases, and
another layer describes the phenotypic interconnections. Disease interconnection studies especially
the HDN ones have significantly advanced biomedical research beyond the individual-disease ones.
LOS and other clinical treatment measures are “correlated with” but not equivalent to genetic risk
factors and phenotypes. As such, the interconnections in LOS (or other clinical treatment measures)
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among diseases cannot be derived from the molecular and phenotypic HDNs. The interconnection
in LOS among diseases has been noted. For example, in a study investigating LOS variations
within the Diagnosis Related Groups, Berki et al. [22] argued that patients with similar diagnostic
and other case-management-relevant characteristics had correlated LOS measures and emphasized
the necessity of jointly analyzing LOS behaviors for diseases homogeneous in clinically relevant
characteristics. Similar arguments have been made in followup studies. However, the existing
studies on LOS interconnections are limited to a small number of diseases. This study, with a
global perspective, is expected to have higher significance, in the same way as the HDN ones.
Interconnections in clinical treatment measures can be caused by shared or causal disease eti-
ology (for example, between breast cancer, ovarian cancer, and other hormone-related diseases;
between diabetes and its complications), shared environmental, dietary, socioeconomic, and other
risk factors (for example, between multiple respiratory diseases that share air pollution as a common
risk factor), shared prevention, diagnosis, and treatment strategies (for example, between diseases
that need radiological treatments), and other factors. In Figure 2.1, we showcase the marginal and
joint distributions of LOS of two common diseases: essential hypertension and diabetes mellitus
without complication. The nonparametric fit (blue line in the scatter plot) clearly shows a positive
correlation. In addition, from the marginal distributions, the zero-inflation nature of data is clear.
Figure 2.1: Joint and marginal distributions of LOS of essential hypertension and diabetes
mellitus without complication
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Government agencies, insurance companies, hospitals, and individuals all manage a large num-
ber of diseases with limited healthcare, financial, and human resources. To more efficiently allocate
and plan hospital beds and other resources, which has public health, economic, and ethical im-
portance, it is critical to go beyond individual diseases, take a global view, and account for the
interconnections among diseases in clinical treatment measure research. For example, as suggested
in other HDN studies, tightly interconnected diseases should be considered together, diseases inter-
connected with a large number of others should receive higher priority, and interventions targeting
factors that affect a group of interconnected diseases can be more efficient and cost-effective. Last
but not least, interconnections in treatment can also informatively reflect intrinsic disease proper-
ties.
This study can complement the existing literature and fill knowledge gaps in multiple ways.
Specifically, it differs from the existing LOS analyses by uniquely focusing on the interconnections
among diseases. It advances from studies that analyze a small number of pre-selected diseases by
conducting analysis at the pan-disease level. It differs from the existing molecular and phenotypic
HDNs by being “closer” to clinical treatments, thus having a higher practical value. In the litera-
ture, the most relevant is perhaps the HDN analysis by Ma et al. [31], which analyzed treatment
costs and demonstrated the significance of analyzing disease interconnections in treatment. The
present study differs from Ma et al. [31] in multiple ways. In particular, Ma et al. [31] analyzed
treatment costs, while we examine LOS. The Taiwan population analyzed in Ma et al. [31] dra-
matically differs from the Medicare population. In terms of methodology, Ma et al. [31] examines
unconditional interconnections, which can be much easier and less informative than conditional
interconnections studied here. In the literature, there is a lack of conditional network analysis
approach tailored to LOS data and, as such, new methodological development is needed. Overall,
this study is warranted beyond the existing literature.
2.2 Data
Medicare is a federal health insurance program for adults aged 65 years and above, certain younger
people with disabilities, and people with end-stage renal disease (permanent kidney failure requiring
dialysis or a transplant). It is estimated that 98% of adults aged 65 and older in the U.S. are enrolled
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in Medicare [2]. The Medicare program accounts for over 99% of death for adults aged 65 and older
and about 40 percent of all inpatient discharges [2, 3]. The Medicare claims are bills for services
provided to the Medicare enrollees. The Center for Medicare & Medicaid Services (CMS) offers a
wide range of claims data that is derived from reimbursement or payment of bills.
In analysis, we first retrieve records on 133 million hospital inpatient admissions for the period
of January 2008 to December 2018. These admissions cover Medicare fee-for-services utilized by 35
million Medicare beneficiaries. We further randomly select data on 100,000 subjects aged 65 years
and above.Published studies [49, 50] suggest that the sample size needed for an accurate network
estimation depends on the complexity of network structure (e.g., number of nodes and sparsity
level). For the proposed analysis, in simulation (details in Section 2.5), we find that a sample size
of 10,000 is sufficient to generate accurate estimation for a variety of settings with 100 nodes. In
data analysis, with 108 nodes, we conservatively choose a sample size of 100,000, which is expected
to be sufficiently large while still being computationally affordable.
For each inpatient claim, there can be up to 25 (1 primary and 24 secondary) diagnosis codes,
which are defined under the International Classification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) for discharges prior to October 1, 2015 and under the International Classifica-
tion of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) otherwise. For each inpatient
treatment episode, LOS is calculated as the length between dates of admission and discharge. To
accommodate multiple possible conditions per visit, we allocate 60% of the LOS to the primary
diagnosis and divide the rest evenly among all secondary diagnoses. For example, if an inpatient
treatment episode involved a LOS of ten days and five diagnosis codes, six days will be attributed
to the primary diagnosis, and one day will be attributed to each of the four secondary diagnoses.
We note that in the literature [51], there is still a lack of consensus on how to allocate among mul-
tiple disease conditions. The adopted allocation ensures that for each visit, the primary diagnosis
dominates and that all comorbidity conditions contribute equally. Then for each subject, LOS for
each disease is summed over all inpatient treatment episodes within the study period. The resulted
analysis dataset has 100,000 observations (one for each subject), and each observation contains the
summed LOS for each disease. A zero-entry means that the subject had not been admitted to
hospitals because of the corresponding disease within the study period.
As can be seen from the marginal distributions in Figure 2.1, in addition to the zero-inflation
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nature, LOS data are also skewed. Following the literature [11,52], we conduct marginal logarithm
transformations for the non-zero data entries. Figure 2.2 shows the distributions of the non-
zero data before and after transformation for essential hypertension, diabetes mellitus without
complication, and glaucoma (as an example of rare diseases). From Figure 2.2 and other alike
(omitted here), we conclude that, although there may still be slight skewness after transformation,
normality can be reasonably assumed.
Figure 2.2: Distributions of non-zero LOS data before and after transformation
Figure 2.3: Flowchart of data processing
Following the literature [28], we exclude the following diseases (codes) from analysis: 1) external
causes of injury and supplemental classification (the E and V codes in ICD-9-CM and V00-Z99 in
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ICD-10-CM); 2) pregnancy, childbirth and puerperium complications (630 – 679 in ICD-9-CM and
O00-O9A in ICD-10-CM); and 3) symptoms, signs & ill-defined conditions (760-999 in ICD-9-CM
and P00-P96, R00-R99, and S00-T88 in ICD-10-CM). This leads to 8,062 ICD-9-CM codes and
17,490 ICD-10-CM codes. To better classify and define human diseases, these diagnosis codes are
further grouped using the Clinical Classifications Software (CCS) developed by the Agency for
Healthcare Research and Quality. CCS is a tool for clustering disease diagnoses into a manageable
number of clinically meaningful categories and has been widely used in a variety of studies related
to diagnoses [53]. To generate more reliable estimates, we focus on common diseases defined as
having a population prevalence of 2% or greater over the 11-year study period, leading to 108
diseases for analysis. More detailed information on these diseases is available in Appendix A.1.
Data processing is also presented in Figure 2.3.
(a) Prevalence
(b) Average LOS
Figure 2.4: Top 10 diseases with the highest prevalence and average LOS
To have an overview of the analyzed data and diseases, Figure 2.4a shows the top 10 diseases
with the highest prevalence (population percentage of non-zero LOS), and Figure 2.4b shows the
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top 10 diseases with the highest average LOS among patients with non-zero LOS. The two plots
include both overall (summarized over 11 years) and yearly values. Prevalence and average LOS
depict from two different perspectives the medical burden from hospitalization. It is observed from
Figure 2.4 that chronic conditions tend to have higher prevalence, and acute conditions tend to
have higher average LOS. Congestive heart failure; nonhypertensive is the only condition that ranks
in the top 10 for both prevalence and average LOS. Temporal variations are also clearly observed
from Figure 2.4. While some diseases consistently rank high, others may only appear in the top
10 lists for a few years. For example, hypertension with complications and secondary hypertension
ranks out of the top 10 in prevalence in early years, but rises in rank rapidly from 2016.
There have been extensive studies on LOS using the Medicare data. In the analysis of individual
diseases, for example, Bueno et al. [54] depicted the trends of LOS and its correlation with other
short-term outcomes of Medicare patients hospitalized for heart failure. In the analysis of diseases
overall, for example, Jencks et al. [55] investigated the correlation between LOS and hospital-
associated mortality for all Medicare patients. As described in the above section, the proposed
analysis fundamentally differs from these two types of analysis.
2.3 Methods
Our goal is to construct a disease network under which each node corresponds to the LOS of one
disease. Two nodes are connected with an edge if the LOS values of the corresponding diseases
are “connected”. In general, there are two families of network constructions: unconditional and
conditional. In unconditional analysis, when investigating whether two diseases are interconnected,
the other diseases are “ignored”. Most of the existing HDNs, including the gene-centric HDN
by Goh et al. [24], phenotypic HDN by Hidalgo et al. [27], and treatment costs network by Ma
et al. [31], belong to this category. In conditional analysis, the goal is to quantify whether two
diseases are interconnected conditional on the other diseases. As established in the literature [56],
conditional networks can be more informative and, at the same time, more challenging.
Graphical models have been widely used in the literature for modeling conditional dependence
among a set of variables. A graphical model is associated with a graph G = (V ;E), where the node
set V represents the variables of interest, and the edge set E encodes the corresponding conditional
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dependence relationships for the node set V . Let nb(v) = {w ∈ V : {w, v} ∈ E} be the neighbors of
node v ∈ V , then Xv – measurement of this node – is conditionally independent of its non-neighbors
XV \(nb(v)∪v) given its neighbors Xnb(v). In a sense, a graphical model is a set of multivariate joint
distributions that exhibit certain conditional dependence. In the statistical literature, the most
popular and developed graphical model is perhaps the Gaussian Graphical Model (GGM), which
assumes that the nodes have a multivariate normal distribution, and two nodes are identified to
be conditionally independent if the corresponding element in the precision matrix (i.e., the inverse
of the covariance matrix) is zero. Another commonly used approach, the Ising model, applies
to the case where all nodes are binary. With the consideration that both assumptions are too
restrictive, multiple efforts have been taken, assuming alternative data distributions. For example
Yang et al. [57] assumed that the node-wise conditional distributions arise from some commonly
used univariate exponential families. Voorman et al. [58] proposed a semi-parametric method and
estimated the graph structure with joint additive models, which allow the conditional means to take
on an arbitrary additive form. Fellinghauer et al. [59] used a Graphical Random Forests method to
estimate the pairwise conditional independence relationships among mixed-type, i.e. continuous and
discrete, variables. Several normal copula and nonparanormal models [60] have also been developed
to accommodate non-Gaussian data. Despite extensive effort, however, a closer examination of the
existing methods shows that they are all not directly applicable to zero-inflated data, as observed in
Figure 2.1.
2.3.1 Modeling
To accommodate the zero-inflation nature of LOS data, and also motivated by individual-disease
LOS analysis [11], we propose employing a multivariate Hurdle model [61]. In general, univariate
Hurdle models arise from modification of a density through exclusion of points in the support and
assignment of positive masses to these points. In our case, to accommodate zero-inflation, the
origin is excluded from the density. Let vy = I{y 6= 0}. Then the Hurdle model derived from a
Normal distribution with mean µ and precision η2 has density:
f(y) = exp{vy[1/2log(η2/(2π)) + logp/(1− p)− µ2η2/2] + yµη2 − y2η2/2 + log(1− p)},
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where p = P (vy = 1) ∈ (0, 1) is the probability of observing a non-zero value.
Built on the univariate Hurdle model, under the multivariate Hurdle model, each conditional
distribution of one node (disease) given the others is a mixture of a point mass at zero and a normal
distribution. Here we note that the original LOS measurements are count data. However, with the
splitting (between the primary and secondary diagnoses) and quite “spread” measurements, it is
reasonable to model LOS as continuous distributions.
Let v = (v1, ..., vd)
T be a d-dimensional binary vector, where d is the number of diseases, and
vj indicates whether a subject has inpatient treatment for the jth disease. Assume that V follows
an Ising model with joint probability:
pv ≡ P (V = v) ∝ exp(vTGv), v ∈ {0, 1}d,
where G is a symmetric interaction matrix in Rd×d, and zero entries indicate conditional indepen-
dence in the occurrence of disease treatment.
Let y ∈ Rd be the vector of LOS of the d diseases. Logarithm transformation for non-zero
data entries is conducted. With a slight abuse of notation, we still use the same notation for the
transformed LOS values, for which normality can be assumed. Consider the distribution:
Y|V ∼ N(µ(v),Σ(v))
with mean vector µ(v) ∈ R2 and covariance matrix Σ(v) ∈ PD(v). Then the conditional distribu-
tion of Y given V = v has log-density:
logf(y|V = v) = vTHy − 1
2
yTKy − C ′(H,K), y ∈ Rv,
where H and K are two d × d interaction matrices that do not vary with v and measure the
dependence between the presence of treatment and LOS and between LOS values respectively,
C ′(H,K) is a normalization constant, and Rv =
∏d
j=1Rvj with R0 = {0}. K is symmetric and
positive definite, but there is no constraint on H. The joint log-density of Y and V is:
logf(y,v) = vTGv + vTHy − 1
2
yTKy − C(G,H,K), y ∈ Rd.
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To quantify pairwise conditional interconnections, the conditional density is derived from the
joint density as follows. For a fixed coordinate b ∈ {1, ..., d}, define its complement A = {1, ..., d} \
{b}. Noting that viyi = yi and v2i = vi, we have the conditional log-density of Yb given YA as:




where the normalization constant C[b|A] does not depend on (yb, vb) and
g[b|A] = gbb + 2gbAvA + hbAyA, h[b|A] = hbb + h
T
AbvA + kbAyA, k[b|A] = kbb.
Based on the conditional distribution, elements in the three interaction matrices G, H, and K,
which quantify pairwise interconnections between diseases conditional on all other diseases, can be
obtained. Following the literature [61], we conclude conditional independence between diseases i
and j if and only if all four ij interaction elements are zero. That is,
gij = hij = hji = kij = 0.
2.3.2 Estimation
Considering the fact that not all diseases are interconnected, and to generate sparse and inter-
pretable networks, we propose conducting sparse estimation. In particular, we adopt the penal-
ization technique [56], which has been widely used in structure learning of the GGM and other
network constructions. It has also been used in the analysis of clinical treatment measures of indi-
vidual diseases [62]. More specifically, for a fixed coordinate b ∈ {1, ..., d}, consider the conditional
distribution of Yb given the other variables in YA for A = {1, ..., d} \ {b}. For a ∈ A, define the
parameter vector θa = (gba, hba, hab, kba)
T . Then Yb ⊥⊥ Ya|YA\{a} if and only if θa = 0. Consider
the penalized objective function:
logf[b|A](yb, vb|yA,vA)− Pλ(θ),
where Pλ(θ) = λ||θa||1 is the LASSO penalty and λ > 0 is the data-dependent tuning parameter.
Note that the above estimation is defined for each coordinate. The estimations of different coordi-
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nates are connected via sharing the same tuning parameter, ensuring a comparable ground for all
nodes.
Computation The penalized objective function is the sum of a smooth convex function g(θ) and
a non-differentiable convex function h(θ). Generically, the optimization problem minθL(θ) =
g(θ) + h(θ) can be tackled using the proximal gradient descent technique [61]. Specifically, the
proximity operator for θ related to t and h is defined as:




‖θ − x‖22 + h(θ),
where t is the step size and h is the LASSO penalty. Then the update rule can be described as
θk+1 = proxh,tk(θ
k − tk∇g(θk)).
For a fixed coordinate b ∈ {1, ..., d}, let θ0 = (gbb, hbb, kbb)T , θa = (gba, hba, hab, kba)T , and
θ = (θT0 ,θ
T
a )
T . The gradients of the log-likelihood function g(θ) = logf[b|A](yb, vb|yA,vA) with
respect to θ can be calculated using the chain rule. As such, the proximal gradient descent-based
neighborhood selection procedure can be conducted for each node. The estimates for G, H, and K
can thus be obtained. More details are available from the authors as well as realized in our code,
which is available at www.github.com/shuanggema. The proposed approach involves the tuning
parameter λ. It is chosen using cross-validation, which has been adopted in penalized GGM and
other network analyses.
With a large sample size, a large number of diseases, and complex model structures (with
multiple interconnection matrices), computation is unfortunately expensive. With a fixed tuning
parameter, analysis takes about two hours. Luckily, estimation under different tunings can be run
in a parallel manner to reduce computer time. For larger data, further parallelization may be
needed to make the analysis affordable.
2.3.3 Analysis of network properties
In a sense, the parameter estimates and model obtained above can fully describe data properties.
However, they may not have lucid interpretations. In network analysis, key properties are usually
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summarized through adjacency, connectivity, module/hub, and other measures [56, 63], which can
provide more meaningful understandings than model parameters only. Similar analysis has been
conducted in the phenotypic and treatment costs HDNs [28,31].
Adjacency matrix The most fundamental property of a network is reflected in the d× d adjacency
matrix, whose elements describe whether a pair of diseases are interconnected conditional on the
others (i.e., whether a linking edge exists). In our model, we conclude conditional independence
between diseases i and j if and only if Gij = Hij = Hji = Kij = 0. More specifically, consider the
estimated interaction matrices Ĝ, Ĥ1 (the estimate of H fitted by column), Ĥ2 (the estimate of H
fitted by row), and K̂. The adjacency matrix A = [aij ] is defined as
aij =
0, if Ĝij < τ & Ĥ1ij < τ & Ĥ2ij < τ & K̂ij < τ1, otherwise
where we further impose a threshold τ to remove spurious small interconnections and generate
sparser and more interpretable networks. τ can be determined data-dependently (for example,
using cross validation) or based on the specific contexts.





which measures how tightly it is connected to the other nodes. For many networks including the
HDNs [28,31], it has been suggested that nodes with higher connectivity values are more important
in a network sense since they have a higher impact overall.
Module Modules have also been referred to as network communities or clusters in the literature.
A module consists of tightly interconnected nodes, and different modules are relatively weakly
interconnected. It has been suggested that nodes within the same module tend to “behave similarly”
and should be considered as a group. In module construction, first consider the topological overlap
matrix (TOM), whose (i, j)th element is defined as
TOMij =
lij + aij





u aiuauj measures how many neighbors that nodes i and j share. Accordingly, the
TOM-based dissimilarity matrix is defined as dissTOM = 1-TOM [63]. Based on dissTOM, which
measures the dissimilarity of any pairs of diseases, modules can then be constructed by hierarchical
clustering with a dynamic tree cutting approach [63]. After module construction, for a node,
its intramodular connectivity, which is connectivity limited to the module it belongs to, can be
computed to reflect “more local” connection properties.
2.4 Data analysis
2.4.1 Network properties
We first consider the “whole picture” with all 11 years combined. With 108 nodes (diseases), the
resulted network has 1,049 edges, with a disease on average connected to 19.4 others. The network
is graphically presented in Figure 2.5 using Gephi. In the plot, a line represents an edge, the size of
a node is proportional to its connectivity, and the color of a node represents its module membership.
Similar constructions and visualizations have been done for individual years. Additional details are
provided in Appendix A.2. Figure 2.5 shows extensive interconnections among nodes. There are
only two diseases that are not linked to any other diseases. This is expected since multimorbidity
is the most common clinical picture of the elderly population [64]. Simply eyeballing the network
suggests that it differs fundamentally from the molecular HDN in Goh et al. [24], phenotypic HDN
in Hidalgo et al. [27], and treatment costs HDN in Ma et al. [31]. This is attributable to differences
in disease definition, approach in network construction, population characteristics, and outcome
measure.
Connectivity Figure 2.6 shows the top 10 diseases with the highest overall and year-specific con-
nectivity values. Comparing it to Figure 2.4 shows that the diseases with the highest connectivity
also tend to have the highest prevalence and possibly the highest LOS. Loosely speaking, these
diseases are the most important. More specifically, all diseases in Figure 2.6 are well-known com-
mon diseases in the elderly population, which provides some support to the validity of our network
analysis. For example, cardiovascular disorders, including congestive heart failure, cardiac dys-
rhythmias, and coronary atherosclerosis, are estimated to be the most common chronic conditions
in the population aged 65 years and above [64]. Systemic diseases like fluid and electrolyte disorders,
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Figure 2.5: Disease LOS network for the period of January 2008 to December 2018
Figure 2.6: Top 10 diseases with the highest overall and yearly connectivity
nervous system disorders, and nutritional, endocrine, and metabolic disorders are also common in
the elderly populations and are expected to have high connectivity because they affect the gen-
eral functioning of the entire body [65]. From a treatment perspective, diseases such as fluid and
electrolyte disorders, acute and unspecified renal failure, and hypertension with complications and
secondary hypertension require extensive care through hospitalizations [66, 67] and are expected
to have high LOS connectivity. In contrast, diseases such as essential hypertension, disorders of
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lipid metabolism, osteoarthritis, and urinary tract infections often do not require hospitalization
but have high connectivity in the constructed LOS network, indicating them to be important co-
morbidities that are connected with other diseases that require higher LOS. For example, serious
osteoarthritis can lead to fractures [68], disorders of lipid metabolism increase the risk of coronary
artery disease [69], and urinary tract infections are highly correlated to septicemia especially in
elderly females [70]. While some individual relationships between a few selected diseases have been
studied in the literature, our results can be informative by looking at all diseases “globally” and
also examining disease pairs less/not investigated. For example, from etiological studies, secondary
hypertension has a closer connection to many other heart and cerebral diseases, urinary diseases,
and endocrine diseases, compared to primary hypertension [71]. However, we show that in the LOS
network, primary hypertension has a higher connectivity. Hypertension is a complicated condition
that individuals generally have different pathogenesis, progression, etiology, and pathophysiology,
and studies on it remain inclusive [67]. Our analysis results may provide additional insights and
also suggest potential future research directions related to hypertension. Such results cannot be
obtained from the individual-disease based.
Module A total of 11 modules are identified, with sizes ranging from 18 to 5. In Figure 2.5, dif-
ferent modules are distinguished using colors. More details on year-specific results are provided
in Appendix A.2. By construction, modules should consist of tightly interconnected diseases. An
enrichment analysis is conducted to examine the representative diseases of different modules. It
is found that the 11 modules are enriched with the following diseases: nervous system diseases
and comorbidities (pink), cardiovascular diseases and complications (light green), gastrointestinal
diseases (celeste), infectious diseases (yellowish brown), respiratory system diseases (orange), cen-
tral nervous system diseases (vermeil), substance abuse disorders and complications (aqua green),
osteoarticular diseases (champagne), urinary system diseases (blue), skin and arthritis infections
(brown), and residual diseases (yellow), respectively.
Module construction can provide an alternative way of disease characterization and classifica-
tion. Classic disease classifications are based on organ, symptom, and phenotype. It has been
recognized that new classifications are needed to serve new purposes [72]. For example, gene-
centric disease classifications have been developed [24] and integrated with classic classifications.
In our LOS disease network, which is closer to clinical practice, diseases form modules not only
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because they share common genetic and environmental risk factors but also because they have
shared treatment strategies. Take the pink module as an example, which is enriched with ner-
vous system diseases. Osteoarthritis, other connective tissue disease, and other non-traumatic
joint disorders have a relatively “long distance” from nervous system diseases based on etiological
studies. However, there is an increasing trend of listing these disorders together with neurological
disorders as an indicator of disease progression and poor prognosis, especially in the elderly popu-
lation [73]. To be more specific, it is common for elderly patients with multiple chronic diseases to
be mobility-impaired. This could cause them to develop various nervous system diseases as well as
osteoarthritis, other connective tissue disease, and other non-traumatic joint disorders.
Within each module, the hub disease is defined as the one with the highest intramodular con-
nectivity. Generically in network analysis, hubs may play central roles in their respective modules
and should be “targeted” first [56]. The hub diseases for the 11 modules are: other nervous sys-
tem disorders (pink), coronary atherosclerosis and other heart disease (light green), diverticulosis
and diverticulitis (celeste), septicemia (yellowish brown), pneumonia (orange), acute cerebrovas-
cular disease (vermeil), chronic obstructive pulmonary disease and bronchiectasis (aqua green),
spondylosis; intervertebral disc disorders; other back problems (champagne), urinary tract infec-
tions (blue), skin and subcutaneous tissue infections (brown), and nutritional deficiencies (yellow),
respectively. All of these diseases have been suggested in the literature as having essential im-
portance for older adults. We note that connectivity and intramodular connectivity are not the
same concept. In particular, connectivity can be potentially affected by a large number of weak
connections, whereas intramodular connectivity better reflects “local properties”. In our analysis,
for example, pneumonia has a low overall connectivity but the highest intramodular connectivity
in the module enriched with respiratory system diseases.
2.4.2 Temporal variation
It is easy to observe variations over time from the above summary statistics. Here we move on with
conducting the above network analysis for each year separately and examining differences across
time. We randomly select the 100,000 samples for each year separately. This way, we can ensure
that representative samples are obtained for all years. We note that if we select and fix a cohort
in year one, it may or may not be representative in the subsequent years. It is also noted that
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temporal variation is not presented with the molecular HDNs (as the molecular basis of most if not
all diseases is stable) and ignored in most of the existing phenotypic HDNs. Temporal variation is
also examined with the treatment costs HDN [31].
Connectivity Figure 2.6 shows the top 10 diseases with the highest yearly connectivity values. While
the structures of high-connectivity diseases for adjacent years are similar, the overall differences
are obvious. Some diseases, such as essential hypertension, fluid and electrolyte disorders, and
disorders lipid metabolism, are stable with high connectivity in almost all years. In contrast, some
other diseases, such as urinary tract infections, osteoarthritis, and septicemia, only appear in the
top 10 lists for a few years. Moreover, a jump in individual disease connectivity between 2010 and
2011 is observed, indicating more intensive interconnections between diseases in the later year. A
closer examination of data and literature suggests that this is at least partly caused by the change
in CMS’ electronic transaction standards that hospitals use to submit Medicare claims. Starting
in January 2011, institutional providers were able to enter up to 25 diagnosis codes for a single
claim, while previously only 9 were allowed [74]. In the retrieved dataset, the average number of
per claim diagnosis codes increases from 8.03 in 2010 to 13.93 in 2011. This can lead to a higher
number of comorbidities per patient and hence a higher disease connectivity. We note that, for the
overall network constructed using all 11 years of data combined, the numbers of comorbidities are
accrued for the entire 11 years of study period, and the policy change in 2011 might not make a big
impact. This is confirmed by repeating the overall network analysis using only the first 9 diagnosis
codes per claim. Assuming physicians enter important diagnoses first, the first 9 existing codes
would be the 9 codes entered if the coding policy had not changed. Therefore, using only the first
9 diagnosis codes mimic the situation that the policy change in 2011 never happened. Comparing
this with the overall network constructed in Section 2.4.1, we observe only ignorable changes in the
network structure (details omitted and available from the authors).
Module To examine yearly variations in disease modules, we compare pairwise disease module
relationships. More specifically, if two diseases are in the same module for one year but not
for the later year, we say their disease module relationship has changed. Figure 2.7a shows the
yearly percentages of pairs of diseases that have changed their module relationships. Overall, we
observe a moderate degree of changes, except for year 2011 where 26% of the pairwise module
relationships have changed. The big change in 2011 is likely also due to the change in CMS’
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(a) Yearly changes in disease module relationships
(b) Modules that contain secondary malignancies in 2014 (left) and 2018 (right)
Figure 2.7: Temporal variations of module structure
electronic transaction standards mentioned earlier. Variations in module relationships can be caused
by multiple reasons, such as changes in risk factors, progress in disease diagnosis, and advances
in treatment strategies. As an example of how disease module memberships may change, Figure
2.7b shows the modules that secondary malignancies (ccs42) belongs to in 2014 and 2018. Thanks
to the innovative cancer immunotherapy technique – immune checkpoint inhibitors (ICPIs), the
landscape of advanced cancer treatment has significantly changed in the last decade. ICPIs has
shown clinically significant antitumor response in multiple cancer types [75]. Since 2015, ICPIs
has been widely used upon the Food and Drug Administration’s approvals and led to significant
improvement in cancer survival [75]. Comparing the module that secondary malignancies belongs
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to in 2014 with that in 2018, we see a big change in the module structure. In Figure 2.7b, common
disease shared by the two modules are colored in green and different diseases are colored in orange.
In 2018, secondary malignancies is no longer clustered with multiple types of skin infections (ccs197
and ccs199) and neuropsychiatric disorders (ccs95, ccs 653, and ccs659), but is clustered with several
intestinal (ccs135 and ccs154), liver (ccs151), and renal disorders (ccs157 and ccs161), all of which
are potential side effects from ICPIs [76].
Remarks Under simpler settings, there are more sophisticated approaches for studying temporal
variations, for example, the time-varying coefficient model. We suspect that it is possible to couple
such techniques with the proposed HDN analysis. However, significant new developments may be
needed. The above examination is simple and can be easier to interpret.
2.4.3 Sensitivity analysis
In the above analysis, for claims with multiple diagnosis codes, we attribute 60% of the LOS to the
primary diagnosis, and the rest 40% evenly to all secondary diagnoses. We would like to note again
that this assignment, although slightly subjective, is sensible, and that there is still no consensus
on splitting LOS (and other treatment measures) among diagnoses. To examine the effects of this
allocation on the findings, we re-conduct the above analysis with all 11 years data combined using
allocations with 70% or 50% to the primary diagnosis and the rest evenly to all secondary diagnoses.
Only ignorable changes in the network structure are observed (details omitted and available from
the authors).
2.4.4 Alternative analysis
For the same CCS diseases, in Appendix A.3, we construct the molecular HDN (using information
extracted from https://phewascatalog.org/phewas) and phenotypic HDN (using the same data as
analyzed above). It is observed that these two HDNs and their key properties differ significantly
from those of the proposed, which further justifies that the proposed disease interconnection analysis
is warranted beyond the existing HDN studies.
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2.5 Simulation
Simulation is conducted to get more insights into performance of the proposed modeling and es-
timation approach. The sample size is fixed as 10,000, and there are 100 nodes (diseases). Note
that the real data has a much larger sample size, and hence more reliable estimation is expected.
We consider a variety of settings with different graph topologies, sparsity levels, and parametric
models. Specifically, with the chain graph topology, the interaction matrices G, H, and K have
banded structures. The numbers of nonzero diagonals depend on the specified sparsity levels. For
example, a 1.5% sparsity results in a band width of three, and a 5% sparsity results in a band width
of seven. With the random graph topology, the interaction matrices G, H, and K have certain
numbers of random off-diagonal entries being nonzero, where the numbers are determined based
on the prespecified sparsity levels. For parametric models, we consider the Hurdle model, Hur-
dle model under contamination with t8 noise, and Gaussian/logistic selection model. The Hurdle
model is said to be G−minimal when only G has nonzero off-diagonal elements and H and K are
diagonal matrices. In this case, the Hurdle model reduces to the logistic/Ising model. The Hurdle
model is said to be complete if for each edge present in the graph, all of the corresponding entries
in each of the three interaction matrices are nonzero [61]. The Gaussian/logistic selection model is
defined as:
Ỹ ∼ N (µ, K), P (Ṽj |Ỹ = ỹ) = logit(a+ bỹj), Y = ỸṼ,
where a and b can be modified to achieve different levels of zero in Y. To make the simulated data
close to the real data (which has 60% - 98% zeros in Y), we choose the off-diagonal values equal
to -2 for G, -1 for H, and 0.5 for K when applicable. a is randomly selected from Uniform[-2, 0]
and b equals 1. Detailed simulation settings are described in Table 3.1.
For each setting, 100 replicates are simulated. In our analysis, the key is the identification of
edges. In Table 3.2, we summarize the mean (standard deviation) percentage of false negative (FN)
and false positive (FP) rates. Satisfactory performance is observed. With the much larger sample
size of the real data, the simulation provides strong confidence in the validity of our findings.
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1. Hurdle model with a G-minimal chain graph and 1.5% sparsity.
2. Hurdle model with a G−H−K-complete chain graph and 1.5% sparsity.
3. Hurdle model with a G-minimal chain graph and 5% sparsity.
4. Hurdle model with a G−H−K-complete chain graph and 5% sparsity.
5. Hurdle model with a G-minimal random graph and 5% sparsity.
6. Hurdle model with a G−H−K-complete random graph and 5% sparsity.
7-12. The same as 1-6, respectively, with nonzero observations contaminated with t8 noise.
13. Gaussian/logistic selection with a diagonal interaction matrix K.
14. Gaussian/logistic selection with a chain graph K and 1.5% sparsity.
15. Gaussian/logistic selection with a chain graph K and 5% sparsity.
16. Gaussian/logistic selection with a random graph K and 5% sparsity.
Table 2.1: Simulation settings
Setting FN(sd) FP(sd) Setting FN(sd) FP(sd)
1 0(0) 0(0) 9 0(0) 0(0)
2 0(0) 0(0) 10 0(0) 2.55%(0.003)
3 0(0) 0(0) 11 2.98%(0.021) 6.09%(0.009)
4 0(0) 1.08%(0.002) 12 1.92%(0.021) 2.30%(0.006)
5 3.19%(0.021) 2.21%(0.003) 13 0(0) 0(0)
6 2.47%(0.026) 0.74%(0.002) 14 0.77%(0.020) 1.56%(0.005)
7 0(0) 0.45%(0.008) 15 3.67%(0.015) 1.81%(0.003)
8 0(0) 0.56%(0.003) 16 7.54%(0.016) 8.44%(0.004)
Table 2.2: Simulation: mean (sd) percentage of FN and FP
2.6 Discussion
In this study, we have developed a HDN built on diseases’ inpatient LOS. To the best of our
knowledge, this is the first of its kind. This analysis can complement the existing individual-disease
and overall LOS analyses as well as the molecular and phenotypic HDNs. This is especially true
considering the significant differences in methodology and findings. As discussed in the first section,
LOS analysis has important implications for managing and planning healthcare and other resources
and can also be informative for reflecting intrinsic disease properties. This network analysis can
provide insights into disease interconnections, assist more efficiently manage/plan resources, and
advance our understanding of diseases. It also complements the existing HDN analysis, in particular
the recent disease treatment costs HDN. It will be important to develop policymaking based on our
findings. However, that is beyond the scope of this article and will be postponed to future research.
Beyond delivering the first disease LOS network and its snapshot and dynamic properties, this
study has also developed a network analysis approach which may have other applications.
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This study inevitably has limitations. LOS only reflects part of the treatment picture. Many
disease episodes are treated outpatient. Chronic diseases are often handled with drug refillings
that do not involve any hospital treatment. It will be of interest to expand the analysis scope
to accommodate other types of treatment. Nevertheless, we note that inpatient treatment, as
the most serious type of treatment, has its own unique value and has been the focus of a large
number of studies. We have considered the whole Medicare population. It will also be of interest to
conduct stratified analysis to better accommodate heterogeneity. As in many other HDN analysis,
our analysis can only infer associations (with undirected networks). Causal analysis would demand
significant additional data. Our examination suggests that the findings are biomedically sensible
to a large extent. However, we are unable to examine all findings considering the large number of
diseases and interconnections. It will also be of interest to examine additional data and provide




Human Disease Network: Analysis of
the Medicare Inpatient Length of
Stay and Readmission Data
3.1 Introduction
Clinical treatment outcomes are defined to measure healthcare quality (e.g., mortality, readmis-
sion, and complication) and efficiency (e.g., length of stay (LOS), outpatient utilization, and medical
costs). For most medical conditions, these outcomes have been extensively studied. Outcome anal-
ysis helps healthcare practitioners carry out more effective and efficient practices, hence further
improve outcomes. For example, Piedmont Healthcare’s evidence-based care standardization for
pneumonia patients resulted in a 56.5% relative reduction in the pneumonia mortality rate and a
9.3% relative reduction in LOS [7]. By improving the analytic platform and advancing its applica-
tions, the University of Texas Medical Branch achieved a 14.5% relative decrease in their 30-day
all-cause readmission rate, resulting in $1.9 million in cost reduction [8]. Therefore, understanding
outcomes is essential in providing patient-centered and value-based healthcare services.
The analysis of clinical treatment outcomes can be generally classified into two families. The
36
first family focuses on a single disease. For example, Feng and Li [11] analyzed LOS for patients
with ischaemic heart disease and identified important risk factors. They observed the zero-inflation
nature of LOS data and conducted a two-part regression analysis to accommodate zero-inflation.
Healthcare outcome data is generally zero-inflated since, for most conditions, only a small portion
of the population would be susceptible and have clinical treatments. The second family focuses
on a general population and studies all diseases combined. For example, using conditional logistic
regression clustered by hospital and generalized estimating equations, Jung et al. [18] compared
all diseases combined readmission rates in two populations: Medicare Advantage and Medicare
Fee-For-Service. Even though both families are considered effective, they ignore the complex inter-
connections among human diseases. By examining LOS correlations within the Diagnosis Related
Groups, Berki et al. [22] indicated a need to analyze and understand LOS behaviors for multiple
diseases. Rinne et al. [23] also identified correlations between readmission rates of chronic obstruc-
tive pulmonary disease and other medical conditions (e.g., heart failure, acute myocardial infarction
(AMI), pneumonia, and stroke). However, these studies are generally limited to a few pre-selected
and closely related diseases.
Another major characteristic of analyzing clinical outcomes is that the practices generally focus
on one single outcome. For instance, Huling et al. [16] proposed a framework to estimate individu-
alized treatment rules targeting to optimize medical costs. They observed the zero-inflation nature
of medical costs data and developed an approach based on the two-part semicontinuous model-
ing. Chatterjee et al. [17] proposed group regularization for zero-inflated count regression models
using a least-squares approximation of the mixture likelihood and applied it to number of doctor
office visits data. Noting that many clinical treatments have complicated effects that can only
be effectively captured on multiple outcome scales, studies have focused on the condition-specific
correlation between multiple outcomes. With interrupted time-series and survival analysis, Gupta
et al. [13] identified a negative relationship between readmission rate and mortality for Medicare
patients hospitalized with heart failure. With multivariate regression analysis, Rinne et al. [14]
found that longer LOS was associated with a higher risk of readmission for veterans with chronic
obstructive pulmonary disease. However, analysis on multiple outcomes is again limited to a single
disease and ignore the complex interconnections among different diseases. To our best knowledge,
there is a lack of work that jointly analyzes multiple outcomes of multiple diseases.
37
This article fills the research gaps by developing a clinical treatment human disease network
(HDN) that quantifies pan-disease level interconnections on multiple outcomes. This is partially
motivated by the emerging HDN analysis in the past two decades. Existing HDN analyses fall into
three families. The first family is referred to as gene-centric such that diseases are interconnected if
they share common genetic risk factors. Goh et al. [24] was the first to develop the concept of HDN
by connecting two diseases if they are associated with the same gene. Follow-up studies include Li
and Agarwal [26] and Barabasi et al. [48], in which links between human diseases represent various
molecular relationships. The second family is based on disease phenotypes such that two diseases
are connected if their phenotypes are correlated (e.g., comorbidity). Hidalgo et al. [27] was the first
to build a phenotypic HDN upon patients’ clinical histories. Follow-up studies include Roque et
al. [29], Jiang et al. [28], and others. The third family, which is relatively new, examines disease
interconnections based on healthcare outcomes. Ma et al. [31] was the first to construct a clinical
treatment HDN by analyzing disease interconnections in medical costs. Mei et al. [77] expanded the
analysis scope to disease interconnections in LOS. Unlike genetic and phenotypic HDNs, a clinical
treatment HDN captures disease interconnections from not only shared causal disease etiology,
shared environmental risk factors, but also shared prevention, diagnosis, and treatment strategies.
Significantly different and advancing from the existing literature, this article builds a high-
dimensional clinical treatment HDN that focuses on disease interconnections in multiple outcomes.
Specifically, we build a HDN that analyzes the Medicare LOS and readmission data. A third pseudo
outcome, which is a binary indicator of treatment presence, is also included in the graphical model
to accommodate zero-inflation. LOS and readmission are two important outcomes that have been
extensively studied. Prolonged LOS and avoidable readmissions impose huge medical burdens on
both hospitals and patients. In the U.S., hospital stays cost the health system at least $377.5
billion per year [19]. While a 30-day all-cause readmission follows 18% of all hospitalizations, 37%
of them are estimated to be avoidable, which cost the healthcare system $25 to $45 billion per
year [78,79]. There have been substantive efforts that target LOS and readmission as indicators of
high-value care [13,46]. Our choice of outcomes is mainly motivated by the high clinical importance
of LOS and readmission, but we note that the proposed method can be easily generalized to other
outcomes.
As the first network tool studying disease interconnections in multiple outcomes, our approach
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differs from existing clinical treatment HDNs not only in outcome measures but also in statistical
techniques. Ma et al. [31] used a two-part model for the marginal distribution of disease-specific
medical costs and a copula-based approach to identify unconditional pairwise interconnection be-
tween medical costs of two diseases. Mei et al. [77] employed the multivariate Hurdle model
to estimate conditional pairwise correlation between LOS of two diseases. While they both ac-
commodate the zero-inflation nature of data, the modeling techniques are not readily applicable
to high-dimensional outcome data. To deal with uniquely challenging data distributions (high-
dimensionality and zero-inflation), this article develops an innovative network modeling strategy
based on the integrative analysis of generalized linear models. Since the proposed approach is
regression-based, it has much more lucid interpretations and can be easily generalized to incorpo-
rate more outcomes of different data types.
The proposed clinical treatment HDN can inform more efficient management of hospital beds
and other resources, which has public health, economic, and ethical importance. For example,
as suggested in other HDN studies, interventions targeting diseases interconnected with many
others can be more efficient and cost-effective. Moreover, tightly interconnected diseases should be
considered together, and factors that affect a group of interconnected diseases should receive higher
priority [28, 31, 48]. This study complements the existing literature in multiple aspects. First, it
advances current outcome analyses by focusing on multiple outcomes at a pan-disease level. Second,
it fosters complex network research. As most developed HDNs estimate unconditional relationships
on one single outcome, we develop a novel graphical model to estimate conditional interconnections
considering multiple outcomes. It also differs from existing molecular and phenotypic HDNs by
being “closer” to clinical treatments, thus having a higher practical value. Last, it provides new
insights into using the large-scaled Medicare database for outcome research and promotes a better
understanding of the Medicare population.
3.2 Data
This article analyzes the Medicare inpatient data from January 2010 to December 2018. Medicare is
a federal health insurance program for adults aged 65 years and above, certain younger people with
disabilities, and people with end-stage renal disease (permanent kidney failure requiring dialysis or
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a transplant).The Medicare data is considered an excellent source for healthcare analytics because
of its universal coverage and high quality. More than 98% of adults over 65 years old in the U.S.
are enrolled in the Medicare program. It is estimated that the program accounts for over 99% of
death for older adults and about 40% of all inpatient discharges [2, 3]. Centers for Medicare &
Medicaid Services (CMS) offers a wide range of claims data that is derived from reimbursement or
payment of bills. Since it is the basis of determination of reimburse eligibility, the Medicare data
is generally of high quality. It also contains broad information such as beneficiary demographics,
provider information, healthcare service utilization, and medical payments, which can fulfill many
research purposes.
3.2.1 Data preparation
In the analysis, we first retrieve records on 108 million inpatient treatment episodes for the period
of January 2010 to December 2018, which cover Medicare inpatient services utilized by 35 million
beneficiaries. Following the literature [80], we exclude patients who were less than 65 years old
at admission, who had less than 30 days of post-discharge Medicare enrollment, and who died in
hospital. We further select a random sample of 100,000 eligible subjects to reduce computation
burden. In network analysis, the complexity of network structure determines the sample size
needed for accurate estimation. We conduct simulation (details in Section 5) and conclude that the
proposed method achieves satisfactory performance with a sample size of 10,000 for 100 nodes, under
a variety of network structures. For real data analysis of 106 nodes (diseases), we conservatively
choose a sample size of 100,000, which is expected to be sufficiently large.
For each inpatient treatment episode, LOS is calculated as the length between dates of admis-
sion and discharge. Readmission is defined following CMS’ public reported measure on the 30-day
risk-standardized hospital-wide readmission [80]. Specifically, the measure captures all-cause un-
planned readmissions that arise from acute clinical events requiring urgent rehospitalization within
30 days of discharge. Planned readmissions, which are not a signal of care quality and are generally
unavoidable, are not considered in the measure. The detailed algorithm on defining 30-day all-cause
unplanned readmissions is available in CMS’ measure methodology report [80]. For one index ad-
mission, if a patient had multiple unplanned admissions within 30 days of discharge, only the first
is considered readmission. However, the readmission could be an index admission for subsequent
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readmissions.
Diseases are defined by diagnosis codes under the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) for discharges before October 1, 2015, and under the
International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) other-
wise. Following the literature [28, 31], we exclude the following diseases (codes) from the analysis:
1) external causes of injury and supplemental classification (the E and V codes in ICD-9-CM and
V00-Z99 in ICD-10-CM); 2) pregnancy, childbirth and puerperium complications (630 – 679 in
ICD-9-CM and O00-O9A in ICD-10-CM); and 3) symptoms, signs & ill-defined conditions (760-
999 in ICD-9-CM and P00-P96, R00-R99, and S00-T88 in ICD-10-CM). This leads to 7,462 ICD-9-
CM codes and 16,682 ICD-10-CM codes. These diagnosis codes are further grouped into clinically
meaningful categories using the Clinical Classifications Software (CCS). CCS is developed by the
Agency for Healthcare Research and Quality to better classify ICD diagnosis codes into convention-
ally defined human diseases. It has been widely adopted in various studies involving analysis of ICD
codes [53]. To generate reliable estimates, we exclude rare diseases with a population prevalence of
less than 2% over the nine years of study period. This leads to 106 CCS diseases for downstream
analysis. Data processing is presented in Figure 3.1. More detailed information on these diseases
is available in Appendix B.1.
Figure 3.1: Flowchart of data processing
For each inpatient claim, there can be up to 25 (1 primary and 24 secondary) diagnosis codes.
As mortality rates have declined and the population has aged, multimorbidity has become prevalent
among older adults. As a result, it is common for one inpatient treatment episode to deal with
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multiple conditions. To accommodate multiple possible conditions per claim, we allocate 60%
of LOS to the primary diagnosis and divide the rest evenly among all secondary diagnoses. For
example, if an inpatient treatment episode involved a LOS of ten days and five diagnosis codes, six
days will be attributed to the primary diagnosis, and one day will be attributed to each of the four
secondary diagnoses. Allocation of number of readmissions is conducted in the same manner. In
the literature, there is no consensus on how to allocate among multiple disease conditions [51]. The
adopted allocation ensures that for each visit, the primary diagnosis dominates and all comorbidity
conditions contribute equally.
After LOS and number of readmissions are defined for each inpatient treatment episode and
allocated to each diagnosis, for each subject and each CCS disease, LOS and number of readmis-
sions are summed over all inpatient treatment episodes within the study period. To accommodate
the zero-inflation nature of data, we introduce a pseudo outcome, which is a binary indicator of
treatment presence. As such, the resulted analysis datasets contain three n× p matrices, where n
is the number of study subjects and p is the number of CCS diseases. The ij-th entry in each of
the three matrices represents treatment presence indicator (binary), total LOS (continuous), and
total number of readmissions (count), respectively, for subject i and disease j.
3.2.2 Data summary
To have an overview of the analyzed data and diseases, Figure 3.2a shows the top 10 diseases with
the highest prevalence (population percentage of subjects who had clinical treatments), Figure 3.2b
shows the top 10 diseases with the highest average LOS among subjects with clinical treatments,
and Figure 3.2c shows the top 10 diseases with the highest average number of readmissions among
subjects with clinical treatments. The three plots include both overall (summarized over nine years)
and yearly values. Prevalence, LOS, and number of readmissions depict from different perspectives
the medical burden from hospitalization. From Figure 3.2, all diseases on the top 10 lists are
well-known common diseases for the elderly population. It is also observed that chronic conditions
tend to have higher prevalence, and acute conditions tend to have higher LOS and number of
readmissions. While the top 10 lists for LOS and readmission are more similar to each other,
congestive heart failure; nonhypertensive is the only condition that ranks in the top 10 for all
three outcomes. Temporal variations are also clearly observed. For both LOS and number of
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readmissions, a decreasing trend is clearly shown in Figure 3.2b and 3.2c, respectively.
As discussed in Section 1, although limited to a few pre-selected and closely related diseases,
interconnections between LOS and readmission among multiple diseases have been noted in the
literature [22, 23]. In Figure 3.3, we showcase the marginal and joint distributions of LOS and
number of readmissions of two common diseases: essential hypertension and disorders of lipid
metabolism. In all four scatter plots, the nonparametric fit (blue line) clearly shows a positive
correlation. In addition, from the marginal distributions, the zero-inflation nature and skewness
of data are obvious. Following the literature [11], we conduct marginal logarithm transformations
for non-zero LOS data entries. Here we note that the original LOS measurements are count data.
However, with the splitting between the primary and secondary diagnoses and summarizing over
the nine years of study period, it is reasonable to model LOS as continuous distributions. Figure
3.4 shows the distributions of non-zero LOS data before and after transformation for essential
hypertension, disorders of lipid metabolism, and other inflammatory condition of skin. Other
inflammatory condition of skin is included as an example of rare diseases. From Figure 3.4 and
other alike (omitted here), we conclude that, although there may still be slight skewness after
transformation, normality can be reasonably assumed. We model the number of readmission data
as zero-inflated count data, and no data transformation is applied.
3.3 Methods
This article aims to construct an undirected (i.e., no causal relationship between diseases) clinical
treatment HDN that each node represents one disease and two nodes are linked with an edge if
they are associated with correlated LOS or number of readmissions. Methods for learning the struc-
ture of undirected networks can be broadly categorized into methods based on unconditional and
conditional associations among variables. Most existing HDN analysis evaluates unconditional re-
lationships such that when determining whether two diseases are interconnected, the other diseases
are “ignored.” For example, the phenotypic HDN by Jiang et al. [28] employed the φ-correlation
to evaluate unconditional pairwise relationships between phenotypes of two diseases. The clinical
treatment HDN by Ma et al. [31] used a two-part model for the marginal distribution of zero-




(c) Average number of readmissions
Figure 3.2: Top 10 diseases with the highest prevalence, average LOS, and average number of
readmissions
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Figure 3.3: Joint and marginal distributions
relationships between the medical payments of two diseases. Considering that unconditional as-
sociations cannot distinguish between direct and indirect relationships, here we aim to conduct
conditional network analysis, by which the interconnection relationship of two diseases is evaluated
conditioning on all other diseases. As established in the literature [56], conditional networks can
be more informative but more challenging.
In the literature, graphical models are widely used for deriving conditional dependence in net-
work analysis. A graphical model is associated with a graph G = (V ;E), where the node set V =
{1, ..., d} represents the variables of interest, and the edge set E ⊆ V ×V encodes the corresponding
conditional dependence relationships for the node set V . Let nb(v) = {w ∈ V : {w, v} ∈ E} be the
neighbors of node v ∈ V . Then if node u /∈ nb(v), Xv and Xu (measurements of node v and u), are
conditionally independent given other variables in the graph. That is:
(u, v) /∈ E iff u ⊥ v|V/u, v.
This is the pairwise Markov property [81], and graph satisfying this property is called conditional
independence graph (CIG).
A CIG is a set of multivariate joint distributions that depicts conditional independence relation-
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Figure 3.4: Distributions of non-zero LOS data before and after transformation
ships. It is advantageous in terms of its good interpretability and visualization capability. There are
various approaches to estimate the structure of a CIG. When the dimension of the feature space
is high, an efficient and popular method is developed on LASSO [81]. Through estimating the
structure of the conditional distribution of each node given others in the graph, the overall graph
structure could be obtained based on the neighborhood of each node. As such, the estimation
could be viewed as a series of variable selection tasks. This is the so-called neighbourhood selection
method. Meinshausen and Buhlmann [81] proposed this idea for the Gaussian Graphical Model,
and Ravikumar et al. [82] extended the application to binary data, wherein the neighborhood of
each node can be estimated independently via linear models or logistic models. Allen and Liu [83]
then used log-linear regressions to estimate the CIG of count data. Efforts has been made to ac-
commodate more data types. For example, Yang et al. [57] employed generalized linear models
(GLMs), and Voorman et al. [58] used penalized generalized additive models for avoiding strict
data assumptions. However, a careful examination shows that when we have multiple information
sources (e.g, multiple outcomes, in our case, LOS and number of readmissions), none of the ex-




To jointly analyze multiple outcomes of different data types and to accommodate zero-inflation,
our method is developed based on the integrative analysis of GLMs. Integrative analysis jointly
analyzes a set of models with similar model structures and closely related response variables. By
assuming model structures to be similar but not completely equivalent, integrative analysis can
detect heterogeneity and utilize information across various data sets, thus lead to more reliable
estimations [84]. We propose an integrative analysis of GLMs, which can accommodate various
data types thus have strong versatility. Let d be the number of diseases, p be the number of
outcomes, and y(k) = (y
(k)
1 , ..., y
(k)
d )
T (k = 1, ..., p) be the observed values for the k − th outcome.
Consider the conditional distribution of the k − th outcome of disease j, given all other diseases,
belongs to the exponential family:
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j ), with ḃk being the first
derivative of bk.
To further model the zero-inflation, we employ the idea of two-part models [11] and introduce
a pseudo outcome y(0) = (y
(0)
1 , ..., y
(0)
d )
T with each element being a binary indicator of treatment
presence of the corresponding disease. Then for disease j, the k − th outcome value is conditional



















, j = 1, ..., d and k = 0, ..., p.
Since elements in y(k) are very closely related, to capture the connectivity between them, we























j , and τ
(k)
j are the parameters to be estimated. Note that the GLMs for different
outcomes of the same disease are also integrated with similar model structures. That is, except for
the intercepts, we let the linear predictors be proportional and controlled by the parameter τ
(k)
j .












j ), it can be shown that u(t) = ḃk
−1
(g−1(t)) = t. Also assume that Y
(0)
j |Y−j ∼ Bernoulli(pj).
Then the log-likelihood of disease j can be derived as:


























where n is the number of subjects.
This article aims is to jointly analyze LOS and number of readmissions. Therefore, we have
d = 2. Let y(0), y(1), and y(2) be values of treatment presence indicator, LOS, and number of


















































respectively. Then the log-likelihood can be derived as:







































With the developed node-wise log-likelihood, we can estimate the structure of the conditional
dependence for each node given all others in the graph, and thereby obtain the overall graph
structure. Specifically, for a fix node j ∈ {1, ..., d}, consider the conditional distribution of Yj
given all other nodes in YM for M = {1, ..., d} \ {j}. For m ∈M, node m and node j are defined





mj = ... = β
(p)
mj = 0
Our estimation method could be viewed as a generalization of the Quasi-likelihood estimation
method. Even if the models are misspecified, consistency could still be achieved if the conditional
expectation and variance are set correctly for y(k)(k = 1, ..., p).
When analyzing disease interconnection relationships at a pan-disease level, it is reasonable to
assume that not all disease are correlated. Therefore, we propose a sparse estimation such that the
estimated network is sparse and interpretable. Here we employ a group LASSO penalty for sparse
estimation, as it has been well established and widely used in HDN analysis [56, 77]. For m ∈M,




mj , ..., β
(p)
mj)
T . As established, Yj ⊥⊥ Ym|YM\{m} if and
only if θm = 0, thus we want the elements of θm to be all zeros or non-zeros at the same time.
To guarantee the uniformity of graph structure, we apply a group LASSO penalty and propose the
penalized objective function:
min
αj ,βj ,τ j





where λ is the tuning parameter controlling penalty strength and is selected data dependently using
cross validation.
Define the parameter vector ψ = (αj ,βj , τ j)
T . It can be observed that the penalized ob-
jective function is a sum of a differentiable convex function g(ψ) = −Lj(αj ,βj , τ j ,Y) and a
non-differentiable convex function h(ψ) = λ
∑
m6=j ||θm||2. Given the structure of the penalized
objective function, it can be optimized using the proximal gradient descent technique, which has
been largely used in other network studies [61, 77]. Specifically, the proximity operator for ψ is
defined as:




‖ψ − x‖22 + h(ψ),
where t is the step size. Then the update rule can be described as
ψk+1 = proxh,tk(ψ
k − tk∇g(ψk)).
The optimum could be achieved by finding the solution ψ? of:
ψ = proxh,tk(ψ − tk∇g(ψ)).
Thus the algorithm terminates when ψk+1 is very close to ψk, i.e., |ψk+1 − ψk| < ε, with ε being
a prespecified threshold.
Since h(ψ) only involves βj , the gradient descent algorithm could be used for updating αj and











, if ||φ(θkm)|| > tkλ
For node j = 1, ..., d, the gradient of the log-likelihood g(ψ) = −Lj(αj ,βj , τ j ,Y) with respect
to ψ can be easily calculated with the chain rule. As such, the neighborhood selection procedure
based on proximal gradient descent can be performed for each node, and the overall graph structure
can thus be estimated. Pseudocode are presented in Algorithm 1.
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θm(m 6= j, j = 1, ..., p);
1: for j = 1, ..., p do




6: αk+1j = α
k
j − tk∂g(αkj );
7: τ k+1j = τ
k
j − tk∂g(τ kj );
8: θk+1m =

0, ||φ(θkm)|| ≤ tkλ
(||φ(θkm)|| − tkλ)φ(θkm)
||φ(θkm)||
, ||φ(θkm)|| > tkλ
;
9: EXIT WHEN |ψk−1 −ψk| < ε
10: k = k + 1
11: end loop
12: return θm(m 6= j);
13: end for
3.3.3 Analysis of network properties
With the graphical model developed in Section 3.3.1 and parameter estimations obtained in Section
3.3.2, we can construct and visualize the desired clinical treatment HDN. In addition, key proper-
ties such as adjacency, connectivity, and module/hub are summarized [56, 63]. Analysis of theses
properties can provide more meaningful interpretations of the network than model parameters only.
Similar analysis has been conducted in the prior phenotypic and clinical treatment HDNs [28,31,77].
Adjacency matrix Elements in the d × d adjacency matrix describe pairwise conditional indepen-
dence, which indicates whether an edge exists between two nodes. In our model, since conditional
independence structure is estimated separately for each node, we conclude conditional indepen-
dence between two diseases i and j if and only if all ij interactive parameters are zeros. That is,
β
(0)
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ij < τ & β̂
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ij < τ & β̂
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ji < τ & β̂
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where a threshold τ is imposed to further remove spurious small interconnections and generate more
interpretable results. τ can be determined data-dependently (for example, using cross validation)
or based on the specific contexts.
Connectivity To what extent one node is connected with other is defined as connectivity. For node





Since higher connectivity means higher overall impact in a network sense, the importance of nodes
with high connectivity is emphasized in many network analysis including the HDNs [28,31].
Module Network modules, also been referred to as network communities or clusters in some stud-
ies, consist of tightly interconnected nodes. There are many approaches in module construction.
Here we adopt the topological overlap matrix (TOM) based method [63] because of its lucid inter-
pretability. The ij-th element of TOM is defined as
TOMij =
lij + aij




u aiuauj measures how many neighbors that nodes i and j share. Accordingly, dis-
similarity matrix, which is defined as dissTOM = 1-TOM, measures the dissimilarity of any pairs
of diseases. Based on dissTOM, modules can then be constructed by hierarchical clustering with
a dynamic tree cutting approach [63]. By definition, diseases within the same module tend to
behave similarly in terms of the outcomes measured, and diseases from different module are rela-
tively weakly connected. Therefore, module analysis provides fundamental information in disease
characterization and classification. After module construction, a node’s intramodular connectivity,
is measured as its connectivity limited to the module it belongs to. Diseases with the highest
intramodular connectivity are referred as the hub diseases. These diseases have a higher impact
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within the module it belongs to.
3.4 Data analysis
Analyzing the Medicare inpatient data from January 2010 to December 2008, the constructed
clinical treatment HDN on LOS and readmission is visualized using Gephi and presented in Figure
3.5. In the graph, each node represents one CCS disease. Two nodes are linked with a line if
they are determined to be interconnected under the framework developed in Section 3.3. The
node size is proportional to its connectivity, and the node color represents its module membership.
There are 106 nodes linked with 1,008 edges and clustered into 9 modules. The network is highly-
interconnected, with every node connected to at least one other. Similar network visualization is
also conducted for each year within the study period and is provided in Appendix B.2.
Figure 3.5: LOS and readmission HDN for the period of January 2010 to December 2018
3.4.1 Connectivity
Figure 3.6 shows the top ten diseases with the highest connectivity. Both overall and yearly values
are provided. Comparing Figure 3.6 to Figure 3.2, diseases with high prevalence tend to have high
connectivity. All diseases in Figure 3.6, except for thyroid disorders, also appear in Figure 3.2a.
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On the contrary, the relationship between disease rank in connectivity and average LOS/number
of readmissions is not apparent. All diseases with high average LOS and number of readmissions
do not appear to have a high connectivity. This finding may provide critical insights into future
policymaking since existing interventions generally focus on individual conditions with outstanding
LOS and readmission rates. For example, in March 2010, the Affordable Care Act established the
Hospital Readmissions Reduction Program (HRRP) to incentivize hospitals to reduce readmissions
among Medicare beneficiaries. Starting in October 2012, the program began to penalize general
acute care hospitals with high risk-adjusted 30-day readmission rates for three target conditions:
AMI, heart failure, and pneumonia. The target conditions are well known to have high readmission
rates, which is also confirmed in Figure 3.2c. However, our network analysis shows that they do not
have a high connectivity in terms of LOS and readmission, even in years before the implementation
of HRRP. Since conditions with higher connectivity values have a higher overall impact within the
network system, it may be necessary for interventions like the HRRP to target diseases shown in
Figure 3.6.
Figure 3.6: Top 10 diseases with the highest overall and yearly connectivity
3.4.2 Module
As shown in Figure 3.5, there are 9 modules whose size ranges from 5 to 20. Modules consist of a
group of diseases that are closely interconnected with each other. Module analysis provides essential
information for disease characterization and classification. An enrichment analysis shows that the
9 modules are enriched with the following diseases: cardiovascular and metabolic diseases (purple),
acute conditions with bad prognosis (green), obstinate and recurrent disorders (blue), controllable
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chronic disorders (orange), secondary diseases and complications (yellow); digestive system dis-
eases (vermeil), genitourinary system diseases (champagne), cerebrovascular disease (brown), and
residual disease (gray), respectively. Widely used classifications of diseases are generally based
on 1) bodily region or system, 2) function or effect, 3) disease pathology, and 4) disease etiology.
Significantly different from existing standards, our analysis provides an alternative way of disease
characterization and classification from a treatment point of view. For example, the green, blue,
and orange modules each contains diseases of various body systems. These diseases have a relatively
long distance considering disease pathology and etiology. However, they share common characteris-
tics in clinical treatments. Precisely, the green module consists of severe and acute conditions that
require immediate treatments. These diseases generally have a poor prognosis, which would result
in prolonged LOS and high readmission rates. The blue module is enriched with chronic conditions
which are usually incurable and require repeated treatments. The orange module contains control-
lable chronic diseases, which do not require extensive inpatient treatments and are often handled
with outpatient treatments and drug refillings.
3.4.3 Hub
Hub diseases are those with the highest intramodular connectivity. For each module, the hub
diseases are: disorders of lipid metabolism and essential hypertension (purple), fluid and electrolyte
disorders (green), chronic kidney disease (blue), esophageal disorders (orange), septicemia (yellow);
deficiency and other anemia (vermeil), hyperplasia of prostate and other diseases of kidney and
ureters (champagne), paralysis (brown), and pneumonia (gray), respectively. It is noted that overall
connectivity and intramodular connectivity describe the importance of diseases from two different
aspects. For example, hyperplasia of prostate, as the hub disease for the module (champagne) of
genitourinary diseases, has a low overall connectivity but a high intramodular connectivity. This is
expected since disorders of the genitourinary system are relatively independent in incidence, most
of which are not significantly related to disorders of other systems [85]. A further literature search
reveals that, while age and sex hormones are two important risk factors, the etiology of prostate
hyperplasia has not been well established [86]. A closer examination of disease interconnected with




Following the literature [27, 28, 77], we examine the temporal variations of network structure by
repeating the above analysis for each year from 2010 to 2018. We select an independent random
sample of 100,000 subjects for each year. The independent sampling ensures that the select sample
represents cohort characteristics for the corresponding year.
Connectivity Temporal variations in connectivity are apparent, as shown in Figure 3.6. Except for
disorders of lipid metabolism and essential hypertension, which have continuously high connectivity
in all years, all other diseases show a noticeable fluctuation in connectivity across time. For example,
chronic kidney disease continuously ranks high (the third highest) in connectivity from 2011 to
2018. However, it has a lower (the eighth highest) overall connectivity due to the really low value
in year 2010. This observation indicates that examining temporal variations, especially recent year
trend, may provide valuable information that could not be obtained through an overall estimation.
Generally speaking, there is an increasing trend in connectivity for most diseases from 2010 to
2018. Contributing factors may include the improvement in healthcare accessibility and technical
advances in diagnosis and treatments. We also observe a jump in individual connectivity from
2010 to 2011. This is mainly due to the change in CMS’ electronic transaction standards that
providers use to submit Medicare claims. Starting in January 2011, institutional providers can
enter up to 25 diagnosis codes for a single claim where previously only 10 were allowed [13]. A
closer examination of the data reveals that the average number of diagnosis codes per Medicare
inpatient claims increased from 8.03 in 2010 to 13.93 in 2011. This policy change causes an increased
number of comorbidities and hence an increased connectivity. However, with the overall network
building on all claims accumulated for 9 years, it is reasonable to believe that all comorbidities
are captured. Therefore, the policy change may significantly impact yearly estimation but will not
affect the overall analysis.
Module To get insights into temporal variations in module membership, we evaluate changes in
pairwise module relationship. If two diseases belong to the same module in one year and belong to
different modules in the following year, we say their module relationship has changed. The converse
also holds true. Figure 3.7a shows the yearly percentage of disease pairs that have changed their
module relationships. There is a moderate change (20% - 30%) in pairwise module relationships
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in all years. The biggest change happens in year 2011, which is possibly also due to the change in
CMS’ electronic transaction standards mentioned above.
(a) Yearly changes in disease module relationships
(b) Modules that contain AMI in 2011 (left) and 2013 (right)
Figure 3.7: Temporal variations of module structure
To have a closer look at how module structures could change, Figure 3.7b shows the modules
that AMI (ccs100) belongs to in 2011 and 2013. Diseases colored in purple are shared diseases in
both years, and those colored in pink appear only in one of the two years. As one of the most
common conditions in older adults, AMI is known to be associated with high medical expenses and
poor prognosis. This is also confirmed in Figure 3.2b and 3.2c, where AMI has the second highest
average LOS and average number of readmissions. For this reason, it is one of the three initial
target conditions of HRRP, which aims to incentivize healthcare providers to reduce readmissions.
The program went effective in October 2012 and resulted in a reduction in unadjusted readmission
rates from 18.9% to 16.0% for AMI [87]. Therefore, we expect a noticeable change in the module
structure containing AMI before and after the implementation of the HRRP. As shown in Figure
3.7b, the module containing AMI has 26 conditionals in 2011 and 16 conditions in 2013. For
both years, AMI is highly interconnected with other cardiovascular diseases, including coronary
57
atherosclerosis and other heart disease (ccs101), congestive heart failure; nonhypertensive (ccs108),
and peripheral and visceral atherosclerosis (ccs114). Fore year 2011, it is clustered with more
diverse disorders, mainly secondary diseases and complications. Given the high prevalence and
intensive treatments for AMI, this observation is very reasonable. However, for year 2013, with a
significant decrease in readmission rates after implementing HRRP, AMI is no long clustered with
various secondary diseases and complications. Instead, the module in 2013 include more heart-
related conditions, including pulmonary heart disease (ccs103), cardiac dysrhythmias (ccs106), and
heart valve disorders (ccs96).
3.4.5 Sensitivity analysis
In data preparation, we allocate 60% of outcome measures (i.e., LOS and number of readmissions)
to the primary diagnosis code and the rest 40% evenly to all secondary diagnosis codes. This
allocation ensures that the primary diagnosis dominates and all secondary diagnoses contribute
evenly. To learn about the impact of this allocation approach on network structure, we conduct
sensitivity analysis, in which we allocate 70% of outcome measures to the primary diagnosis and the
rest 30% evenly to all secondary diagnoses. The above analysis in network structure and properties
is repeated using combined data for the whole study period, and only ignorable differences are
observed (details omitted and available from the authors).
3.4.6 Comparison to the LOS HDN
Comparing to the LOS HDN constructed in Chapter 2, the network incorporating both LOS and
readmission has a similar structure. Specifically, both networks are highly interconnected with a
comparable level of sparsity. High connectivity and hub diseases such as essential hypertension,
disorders of lipid metabolism, and fluid and electrolyte disorders are consistently identified. Com-
paring Figure 2.6 with Figure 3.6, chronic kidney disease and diabetes mellitus without complication
are the only two diseases that appear on the top 10 connectivity lists for the LOS and readmission
HDN but not on that for the LOS HDN. Moreover, the jump in connectivity from 2010 to 2011
due to the change in CMS’ electronic transaction standards are also captured by both networks.
Despite the similarities, the two networks are different in several ways. Comparing Figure 2.5 with
Figure 3.5, in the LOS and readmission HDN, there are several really big nodes with more number
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of small sized nodes on the periphery of the network. This means that central diseases are intercon-
nected with a larger number of other disease and are better recognized when adding readmission
to the network construction. Moreover, modules constructed in Chapter 2 have more traditional
interpretations in terms of bodily system, disease pathology, and disease etiology. Analyzing both
LOS and readmission, modules constructed in this chapter consist of similar diseases from a treat-
ment perspective. The yearly changes in pairwise module relationships are also observed to be
higher in the network on LOS and readmission, compared to that on LOS only. These deviations
are attributable to different outcomes evaluated and different modeling approaches utilized.
3.5 Simulation
Simulation is conducted to learn about performance of the proposed modeling and estimation
approach. For simulated datasets, we consider a variety of settings with different graph theories
(e.g., dependency network and star graph) and sparsity levels.
A dependency network [88] could be viewed as a mechanism for combining regression/classification
models via Gibbs sampler to define a joint distribution. For example, in Bayesian network, joint
distributions are defined using the product of local distributions. In our simulations, to generalize
multiple interconnected data sets, integrated generalized linear models developed in section 3.3.1
are used here to define local distributions. For βj (j = 1, ..., p), we construct three interactive ma-
trices M(β(0)), M(β(1)) and M(β(2)), indicating parameters in β(0),β(1), andβ(2), respectively.
Noting that the diagonal elements have no actual impact, we set them to be 1 for convenience. We
assume that the interactive matrices have a diagonal structure, a banded structures, or an expo-
nential attenuation structure. For the banded structure, the numbers of nonzero diagonals depend
on a prespecified sparsity levels. For example, a 1.5% sparsity level results in a band width of three
(i.e., a tri-diagonal matrix), and a 5% sparsity level results in a band width of seven. Non-zero
elements in matrices with a banded structure are set to be 0.1 or 0.5. For the exponential attenu-
ation structure, we consider an attenuation factor of 0.5. We also impose blocks on the interactive
matrices, such that nodes in different blocks are conditionally independent.
A star graph [82] consists of sets of mutually independent nodes linked to one seed nodes (i.e.,
a tree with one internal node and leaves). In the simulated data sets, we distributed the variables
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equally based on the number of seeds. For example, if there are 5 seed nodes and 100 variables in
total, we split the variables evenly into 5 groups with one seed per group. Again, the number of
leaves in each group depends on a prespecified sparsity levels. For example, if the sparsity level
is 0.5, then the seed node is expected to be linked with half of other nodes in its group. With
exact sampling, data sets are sampled from models developed in section 3.3.1. β in each model are
randomly generated from N(0, 0.25).
Detailed simulation settings are described in Table 3.1. Coefficients other than β are randomly
generated from prespecified distributions, which are presented in Table 3.2. To reduce computation
burden, we fix the sample size as 10,000 and the node size as 100. We note that for real data analysis,
a much larger sample size is used for a similar number of nodes, hence more reliable estimation is
expected.
Dependency network
1 M(β(0)) has a banded structure with sparsity level 1.5%; M(β(1)) and M(β(2) are diagonal
2 M(β(0)), M(β(1)) and M(β(2)) all have a banded structure with sparsity level 1.5%
3 M(β(0)) has an exponential attenuation structure; M(β(1)) and M(β(2)) are diagonal
4 M(β(0)), M(β(1)) and M(β(2)) all have exponential attenuation structure
5 M(β(0)) has a banded structure with sparsity level 5%; M(β(1)) and M(β(2)) are diagonal
6 M(β(0)), M(β(1)) and M(β(2)) all have banded structure with sparsity level 5%
7-10 Five blocks of settings 3-6, respectively
Star graph
11 One seed with a sparsity level of 0.7
12 Five seed with a sparsity level is 0.5
13 Five seed with a sparsity level is 0.7
14 Ten seed with a sparsity level is 0.7
Table 3.1: Simulation settings
α for seeds in star graph N(0, 0.25)
α for dependency network and non-seeds in star graph N(0, 1)
τ N(1, 0.01)
σ2 1
Table 3.2: Coefficient generation
To gain more insights into the relative performance of our approach compared to two alter-
native approaches, we compute and compare the area under the receiver operating characteristic
curve (AUC) using different methods. The first alternative approach conducts a regression analysis
separately for each of the three outcomes: treatment presence, LOS, and number of readmissions.
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Estimated coefficients indicate conditional pairwise relationship considering a single outcome. Con-
ditional independence is then concluded between two diseases if the corresponding coefficients in
all three models are estimated to be zero. The second alternative approach computes the uncon-
ditional pairwise Spearman correlation for measures of all three outcomes as a vector. For each
setting, 100 replicates are simulated. In network analysis, the key is to accurately identify edges.
In Table 3.3, we summarize the mean AUC and corresponding standard deviation, which shows
that the proposed approach outperforms the two alternative approaches in all 14 settings. The
simulation results provide strong confidence in the validity of our findings.
Setting Proposed Alternative1 Alternative2
1 94.61% (0.03) 87.81% (0.09) 85.90% (0.10)
2 96.50% (0.02) 85.86% (0.06) 83.00% (0.07)
3 94.75% (0.02) 89.24% (0.03) 87.13% (0.04)
4 94.99% (0.02) 85.44% (0.04) 81.12% (0.06)
5 95.40% (0.01) 95.03% (0.02) 91.48% (0.04)
6 87.11% (0.05) 79.94% (0.06) 67.70% (0.06)
7 94.53% (0.02) 86.77% (0.04) 85.40% (0.05)
8 93.14% (0.03) 81.57% (0.03) 76.83% (0.04)
9 94.88% (0.03) 92.35% (0.03) 88.20% (0.03)
10 87.96% (0.07) 81.86% (0.06) 73.10% (0.06)
11 84.90% (0.02) 76.48% (0.02) 81.42% (0.02)
12 94.17% (0.01) 72.14% (0.02) 78.54% (0.03)
13 83.43% (0.03) 77.80% (0.02) 80.14% (0.02)
14 86.90% (0.02) 73.59% (0.02) 79.23% (0.02)
Table 3.3: Simulation results: mean AUC (sd)
3.6 Discussion
In this article, we construct a clinical treatment HDN building on disease associated LOS and
number of readmissions. The analysis can complement the existing literature in multiple ways.
First, it complements the individual-disease and overall outcome analyses by focusing on pan-
disease level interconnections. Second, the proposed clinical treatment HDN complement existing
molecular and phenotypic HDNs by being “closer” to clinical treatments and thus having a higher
practical value. Third, the network analysis on LOS and readmission complements existing clinical
treatment HDNs (e.g., medical costs HDN by Ma et al. [31] and LOS HDN by Mei et al. [77])
by incorporating multiple outcomes. As discussed in Section 3.1, outcome analysis has important
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implication for evaluating and improving healthcare quality and efficiancy, as well as infomatively
reflect intrinsic disease properties. The proposed analysis on LOS and readmission can foster a
better understanding of disease interconnections in term of healthcare outcomes, provide insights
into a better disease management, and guide a more efficient allocation of hospital beds and other
resources. In addition, the novel analytic approach developed for constructing a high-dimensional
and conditional network using zero-inflated data may further complex network analysis.
This article has certain limitations. Due to limited data access, we focus on inpatient treatment
only. Although inpatient treatment deals with the most serious diseases and consumes the most
healthcare resources, it is only part of the healthcare system for the Medicare beneficiaries. In
addition, LOS and readmission only describe part of the medical burden from inpatient treatment.
With more data, it would be of interest to expand the analysis to incorporate other types of
treatment (e.g., outpatient treatment and drug prescription) and other outcomes (e.g., number of
office visits and medical costs). It is noted that the proposed modeling approach is regression-based
and can be easily expanded to accommodate more outcomes of different data types. In the analysis,
we examine the temporal variations in a cross-sectional manner. It is a common approach that
has been largely used in studies on temporal variations in the healthcare domain [89,90], including
existing phenotype [27, 28] and clinical treatment [31, 77] HDNs. With the consideration that we
have observed remarkable dynamics in network structures across time, it will be of interest to
develop a time-varying network framework. This will require extensive methodology development
and will be postpone to future studies. Another limitation associated with the proposed model
is that its computation is more expensive as compared to generally used unconditional models.
The graphical algorithm presented in this article deals with a large sample size, a large number of
unknown parameters, and a complex model structure. Although estimation for different nodes and
under different tuning can be run in a parallel manner to reduce computation time, for large data,




via Clinical Trial Emulation and a Big
Data Approach
4.1 Testing the effectiveness and safety of rivaroxaban and dabi-
gatran for atrial fibrillation via an emulation analysis of the
Medicare data
4.1.1 Introduction
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular heart
chamber beatings. It affects three to six million people in the U.S. alone [91], among whom 85%
to 90% are eligible for oral anticoagulation therapies [92, 93]. As well established in the literature,
it is of great significance to properly choose among non-vitamin K antagonist oral anticoagulants
(NOACs). Rivaroxaban and dabigatran were approved by the U.S. FDA in November 2011 and
October 2010, respectively. They were the first and second NOACs marketed for preventing stroke
among people with non-valvular AF, and have been widely used since marketing. A study shows
that in 2014, they accounted for 74% NOAC prescription during AF office visits [94].
In general, to draw definitive and objective conclusions on a drug’s treatment effects, well-
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controlled randomized clinical trials are needed. There have been multiple trials comparing dabi-
gatran with Warfarin (for example, the RE-LY trial [95]) and rivaroxaban with Warfarin (for
example, the ROCKET-AF trial [96]). These trials show that both rivaroxaban and dabigatran
are non-inferior to Warfarin in preventing stroke and reducing the risk of bleeding. Recent effort
has also been made to compare rivaroxaban with dabigatran. Examples include the DARING-AF
and DANNOAC-AF studies [97,98]. However, they have limited sample sizes and broadly consider
anticoagulants without focusing on rivaroxaban against dabigatran directly.
With the high popularity of these two drugs, it is of high interest to conduct a direct and focused
comparative study. However, with the potentially high cost and the already broad usage of both
drugs, such a randomized clinical trial is not foreseeable in the near future. To tackle this problem,
we resort to the analysis of existing observational data, whose cost is negligible compared to that of
a clinical trial. For this specific comparison problem, observational data has additional advantages.
For example, it has been noted that the administration and adherence patterns of rivaroxaban and
dabigatran are different. In the existing trials, according to the drug instructions, the rivaroxaban
group took pills once a day together with an evening meal, and the dabigatran group took pills
twice daily. It has been suggested that such differences can lead to different adherence patterns,
and these differences further differ between controlled clinical trials and real-world practice [99].
From a public health perspective, real-world clinical practice, which also accommodates the effects
of behavioral factors, can be of more interest. In this perspective, observational data may more
honestly reflect the real-world treatment effects. In addition, as to be shown below, the available
observational data is also considerably larger than many clinical trials on related regimens.
With observational data, the most straightforward approach is to conduct a multivariate re-
gression analysis, as has been pursued on this topic in several publications [100–102]. It has been
well recognized that the associations observed in regression, even after controlling for confound-
ing, may not reflect the desired causal treatment effects. Causal inference with observational data
is a “classic” and broad field. The existing literature is vast and has been reviewed in multiple
publications. For relevant discussions, we refer to Hernan and Robins [36] and references therein.
It is noted that different approaches have different advantages and disadvantages, and that there
is no dominating approach. In this study, we adopt the emulation approach [37], which has been
developed through a series of publications on a variety of illness conditions and treatment strate-
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gies [103–106]. Under emulation, clinical trials are explicitly assembled using observational data,
and statistical techniques for randomized clinical trials can be directly applied. As such, compared
to causal inference techniques such as TMLE [34] and BART [35], emulation can have much more
lucid interpretations.
In this article, our goal is to conduct a direct comparison of rivaroxaban and dabigatran and
draw more definitive conclusions on their relative treatment effects, which can potentially have high
public health implications. Without an actual clinical trial, we analyze the observational data in
Medicare. This database has been chosen because of its broad coverage (hence more power and
a better reflection of the general population in the U.S.) and high data quality. In addition, AF
and the utilization of rivaroxaban and dabigatran can be much more prevalent in the Medicare
population than others. This study may advance the existing literature in multiple aspects. First,
it focuses on rivaroxaban and dabigatran and targets at conducting a direct comparison. Second,
it adopts the emulation approach to explicitly “assemble” a clinical trial using observational data.
The conclusion so drawn can be more informative than those from regression analysis and more
lucid/interpretable than those using some other causal inference techniques. Third, it showcases a
new way of analyzing the Medicare data to better inform clinical practice. Last, it also marks a new
application of the emulation technique. In addition, we also examine temporal variations, which
have been largely neglected in published emulation studies. Overall, this study may provide a useful
complement to the existing AF, clinical trial, emulation, and Medicare data analysis literature.
4.1.2 Data source and study population
Medicare is a national health insurance program in the U.S. The Medicare claims are bills for
services provided to the Medicare beneficiaries: adults aged 65 years and above, certain younger
people with disabilities, and people with end-stage renal diseases [2]. Data analyzed in this study
is extracted from the Centers for Medicare & Medicaid Services (CMS) Chronic Conditions Data
Warehouse (CCW). The CMS CCW offers a wide range of claims data that follows beneficiaries
across multiple care settings. For our analysis particularly, the Part A inpatient data and Part D
prescription drug event data are used to identify eligible study subjects (more details in Section
4.1.3). The Medicare beneficiary identification number is used to link beneficiaries between the two
datasets.
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Our study focuses on the subpopulation with multiple chronic conditions (MCCs). This sub-
population has also been studied for cardiometabolic conditions [107, 108] and diabetes [109, 110],
among others. Health-wise, this subpopulation is more vulnerable. In particular, 80% of AF
happens to patients 65 years old and above [91], and AF is often associated with MCCs such as
diabetes, dementia, and other heart diseases [92]. We further limit our study period to 2012-2013.
The consideration is that by early 2012, both drugs were already extensively used (as such, a large
sample size/sufficient power and broad representativeness can be achieved). A two-year study pe-
riod is “normal” for a real phase III clinical trial. In addition, sufficiently detailed drug utilization
information after 2013 is unavailable to our study. As such, we are unable to determine drug con-
tinuation or switch afterward. Overall, the source population includes 35,758,327 subjects (before
patient selection), among whom 179,510 had taken rivaroxaban or dabigatran during the study
period (more details in Section 4.1.3).
4.1.3 Methods
As established in the literature [37], under the emulation analysis framework, the first step is to
develop a randomized clinical trial protocol. The trial can be a real one, a “hypothetical” one, or
a mixture of both. Then an observational data analysis protocol is developed to emulate this trial.
Accordingly, in section the targeted randomized clinical trial, we first develop the trial protocol.
As there is no existing trial that directly compares rivaroxaban and dabigatran, our design has
been based on relevant trials particularly including the RELY and ROCKET-AF trials as well as
observational data analysis [111,112]. The emulated trial is designed in section the emulated trial,
with its analysis approaches described in section analysis of the emulated trial.
The targeted randomized clinical trial
The goal of the randomized clinical trial is to compare effectiveness (prevention of stroke and other
thromboembolic events) and safety (bleeding and mortality) between standard-dose rivaroxaban
and dabigatran in patients with both non-valvular AF and MCCs.
The first step is to define the inclusion/exclusion criteria. The target trial enrolls participants 65
years old and above, who are diagnosed with non-valvular AF within three months before enrollment
and have MCCs. A participant is excluded if one or more of the following criteria are met: 1) a
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prescription of an anticoagulant within three months before study entry, which may increase the
risk of bleeding; 2) a NOAC preference different from the tested drugs; 3) indications other than
AF for the respective anticoagulant (mitral valve disease, heart valve repair or replacement, deep
vein thrombosis, pulmonary embolism, or joint replacement) in the three months preceding study
entry; 4) being in a skilled nursing facility, receiving hospice care, or being in hospitalization; and
5) having had a kidney transplant or undergoing dialysis.
The trial starts on 01/01/2012. A three-month washout period is adopted with the consid-
eration that anticoagulants used in AF are usually prescribed in 30-day or 90-day cycles. This
ensures that there would be no previous usage of anticoagulants that potentially influence our out-
comes of interest. The trial closes on 12/31/2013. An overall two-year study period is normal for
peer cardiovascular trials. To gain insights into potential temporal variations (which have been
largely neglected in both real and emulated trials), we further dissect the 21-month study period
into three equal intervals. As such, there are a total of three trials, each with a seven-month re-
cruitment period. As the whole study terminates on 12/31/2013, the three trials have different
lengths of follow-up, which may provide insights into the impact of follow-up length on clinical trial
observations.
After recruitment, an eligible participant is randomly assigned to one of two treatment arms.
One arm receives rivaroxaban 20 mg once daily, and the other arm receives dabigatran 150 mg twice
daily. Each participant is followed until death, loss to follow-up, or end of the study (12/31/2013).
A loss to follow-up is defined as a discontinuation of treatment (a gap in the assigned treatment
for over 60 days) or switching NOAC or dosage, whichever occurs first.
The primary outcomes include time to ischemic stroke, other thromboembolic events (systemic
embolism, transient ischemic attack, pulmonary embolism), major bleeding, all-cause death, and
the first occurrence of any of the above. The secondary outcomes include time to any bleeding and
acute myocardial infarction (AMI).
The emulated trial
The emulated trial has been designed largely in line with that described above. More specifically,
we first identify Medicare beneficiaries who filed the first prescription for either rivaroxaban or dabi-
gatran with the standard dosages between 04/01/2012 and 12/31/2013. We start from 04/01/2012
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to ensure participants’ three-month medical history is available to determine whether the washout
period eligibility is satisfied. We define the first prescription date as the index date. We include
only individuals who were 65 years old or above, had at least three months of continuous enroll-
ment in Medicare, and had MCCs. We exclude a subject if one or more of the following criteria
are met: 1) a prescription of an anticoagulant within three months before the index date (has not
been washed-out); 2) a diagnosis indicating a potential alternative indication other than AF for
anticoagulation within three months before the index date; 3) being in a skilled nursing facility,
receiving hospice care, or being in hospitalization; and 4) having had a kidney transplant or un-
dergoing dialysis. We also exclude individuals with incomplete data for potential confounders at
the baseline (0.54% percentage, thus we go for complete case analysis). Information on the list of
confounders is provided in Table 4.1. Additional information on patient selection is provided in the
flowchart in Figure 4.1, and related drug names and ICD-9-CM codes are provided in Appendix
Table C.1 and C.2.
Then the eligible subjects are classified into two treatment groups: rivaroxaban and dabigatran.
Follow-up information is extracted for each subject (to death, loss to follow-up, or end of the study
– 12/31/2013). To identify the primary outcome, we track the study subjects to their first Medicare
inpatient claims with the primary diagnosis code indicating each of the following: ischemic stroke,
other thromboembolic events, major bleeding, and all-cause death. For secondary outcomes, we
also identify all occurrences of any bleeding event (including major bleeding) and AMI in the same
manner. Detailed information on the ICD-9-CM codes for identifying these events is provided in
Appendix Table C.3.
We then create three subsequent emulated trials to examine potential temporal variations. The
same criteria and procedures are applied to the three trials to ensure comparability. All trials then
have a seven-month recruitment period. However, they have different lengths of follow-up. Detailed
information on the sizes of each trial is provided in Figure 4.1.
Analysis of the emulated trial
It has been recognized that an emulated trial may still differ from its real counterpart in multiple
ways. We refer to Hernan and Robins [37] and Danaei et al [104] for discussions. As such, the
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- 10,454 were less than 65 years old 
- 2,977 had less than three months of 
continuous Medicare enrollment 
before the index date 
Trial 1 (04/01/2012 – 10/31/2012) 
Rivaroxaban: 5,880 
Dabigatran: 12,170 
Trial 3 (06/01/2013 – 12/31/2013) 
Rivaroxaban: 16,583 
Dabigatran: 9,184 
Individuals who had a diagnosis of atrial 
fibrillation: 
179,510 
Trial 2 (11/01/2012 – 05/31/2013) 
Rivaroxaban: 14,572 
Dabigatran: 14,308 
- 60,214 filled at least one claim for any 
NOAC within the three-month period 
before the index date 
- 29,675 were kidney transplant recipients, 
undergoing dialysis, diagnosed with other 
potential NOAC indications  
- 1,932 were in hospital on the index date 
- 2,187 were in skilled nursing facility or 
hospice on the index date 
Figure 4.1: Flowchart of assembling clinical trials
differences.
First, to emulate the estimation of an intention-to-treat effect, which is common in real clinical
trials, we use the observed therapy initiation (the first fill of rivaroxaban or dabigatran, the analog
of random assignment in a clinical trial) as the treatment indicator. An observation is censored
when a participant discontinued or switched therapy.
In a well-executed randomized clinical trial, different arms can be sufficiently balanced. As such,
there may be no need for accounting for confounding – although it is noted that it is still commonly
done out of caution. With emulated trials, since randomization does not really happen, there is a
risk of imbalance. As such, as suggested in the literature [37], accounting for potential confounding is
strongly recommended in emulation trial analysis. By reviewing the existing trials including RE-LY
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and ROCKET-AF and published observational studies [111,112], and also taking into consideration
data availability, we include the following variables as potential confounders: demographic variables
(age, gender, race), medical conditions (AMI, congestive heart failure, previous stroke or transient
ischemic attack, diabetes mellitus, hypertension, chronic kidney disease (CKD), history of bleeding,
acquired hypothyroidism, and the number of other CMS comorbidities), and medication use (non-
steroidal anti-inflammatory drug and antiplatelet). Information is also provided in Table 4.1.
For each emulated trial and each outcome, we fit a Cox proportional hazards model, including
the treatment indicator and all baseline confounders as covariates. To further achieve balance as in a
randomized clinical trial, we resort to the propensity score and inverse probability treatment (IPT)
weighting approach. In particular, to calculate the propensity score, we estimate the probability of
having a specific treatment using a logistic model and include the same set of baseline confounders
as covariates [113]. Then the weight is calculated as the inverse of the propensity score for one
treatment group and the inverse of one minus propensity score for the other group. By assigning
such weights to study subjects, we create a pseudo-population, for which there exists no association
between the baseline confounders and treatment.
With the three emulated trials, the above analysis can generate three sets of estimates. Beyond
examining them individually, we also pooled the individual effect together and generated unified
estimations. In particular, we adopt a random effect mixed model approach [114], which decomposes
within-study and between-study variations and computes a weighted and combined effect.
Remarks
In some emulation studies [104,105,115], the sequential trial concept and corresponding techniques
have been developed. Our setting has similarity with the sequential trials in that we also have
three trials conducted in a consecutive manner. However, we note that the current setting can be
somewhat simpler compared to that in Danaei et al [104], Caniglia et al [105], and some others.
First, we study the direct comparison of two treatment drugs without having controls “waiting for”
the switch to treatment, which creates significant overlaps between trials. Second, the number of
subjects included in more than one trial is only 3.54%, dramatically smaller than many existing
emulation studies. With such a small overlap, we are able to mostly ignore the potential correlations
between trials. Another difference is that we allow temporal variations, as opposed to assuming
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the same treatment effects. As such, we do not have the “inference with correlated trials” problem.
4.1.4 Results
Patient characteristics and unadjusted incidences
As shown in Figure 4.1, our analysis includes a total of 70,129 eligible participants, with 18,050,
28,880, and 25,767 in each of the three emulated trials, respectively. Table 4.1 shows the baseline
characteristics by trial and treatment. It is observed that before IPT weighting, participants
treated with rivaroxaban are slightly younger, more likely to be female, and with somewhat less
cardiovascular disease history.
Variables Trial 1 Trial 2 Trial 3
R D R D R D
Demographics
Age(years)
65-74 2898 (49.29) 5850 (48.07) 6817 (46.78) 6553 (45.80) 8313 (50.13) 4433 (48.27)
75-84 2395 (40.73) 4935 (40.55) 6044 (41.48) 5947 (41.56) 6720 (40.52) 3745 (40.78)
≥ 85 587 (9.98) 1385 (11.38) 1711 (11.74) 1808 (12.64) 1550 (9.35) 1006 (10.95)
Sex (female) 2882 (49.01) 5910 (45.56) 7000 (48.04) 6540 (45.71) 7978 (48.11) 4155 (45.24)
Race
White 5450 (93.19) 111016(90.94) 13478 (92.82) 13261 (93.11) 15185 (92.25) 8351 (91.46)
Black 192 (3.28) 533 (4.40) 563 (3.88) 512 (3.59) 678 (4.12) 428 (4.69)
Other 206 (3.52) 465 (4.66) 479 (3.30) 470 (3.30) 597 (3.63) 352 (3.85)
Medical history
Diabetes mellitus 2327 (39.57) 5228 (42.96) 6071 (41.66) 6319 (44.16) 6984 (42.12) 4005 (43.61)
Hypertension 5382 (91.53) 11304 (92.88) 13496 (92.62) 13476 (94.19) 15287 (92.18) 8567 (93.28)
CKD 1359 (23.11) 3378 (27.76) 3659 (25.11) 3957 (27.66) 4339 (26.17) 2683 (29.21)
History of bleeding 128 (2.18) 290 (2.38) 370 (2.54) 402 (2.81) 416 (2.49) 270 (2.94)
Acquired HT 1670 (28.40) 3378 (27.76) 4210 (28.89) 4246 (29.68) 4840 (29.19) 2743 (29.87)
No. of other
CMS comorbidities
0-3 1621 (27.57) 3310 (27.20) 3672 (25.20) 3462 (24.20) 4499 (27.13) 2382 (25.94)
4-6 2836 (48.23) 5711 (46.93) 7106 (48.76) 7024 (49.09) 7930 (47.82) 4334 (47.19)
≤ 7 1423 (24.20) 2149 (25.88) 3794 (26.04) 3822 (26.71) 4154 (25.05) 2468 (26.87)
Cardiovascular disease
AMI 429 (7.30) 940 (7.72) 1106 (7.59) 1092 (7.63) 1317 (7.94) 659 (7.18)
CHF 2501 (42.53) 5912 (48.58) 6618 (45.42) 7256 (50.71) 7227 (43.58) 4484 (48.82)
Stroke or TIA 1189 (20.22) 2853 (23.44) 3094 (21.23) 3351 (23.42) 3616 (21.81) 2163 (23.55)
Medication use
NSAIDs 510 (8.67) 1054 (8.66) 1072 (7.36) 890 (6.22) 1355 (8.17) 616 (6.71)
Antiplatelet 760 (12.93) 1291 (10.61) 1577 (10.82) 1044 (7.30) 1977 (11.92) 711 (7.74)
R rivaroxaban, D dabigatran, CMS centers for Medicare & Medicaid Services,CKD chronic kidney disease,
AMI acute myocardial infarction, CHF congestive heart failure, TIA transient ischemic attack, HT hypothyroidism,
NSAIDs non-steroidal anti-inflammatory drug
Table 4.1: Baseline characteristics of the study cohorts, before IPT weighting
We then examine the temporal variations of the baseline characteristics across the three emu-
lated trials. It is observed that for both the rivaroxaban and dabigatran arms, most of the baseline
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characteristics do not change substantially over time. We do observe that the number of patients
with CKD obviously rose during the two years. For rivaroxaban, the percentage of patients with
CKD rose from 23.11% to 25.11% and then to 26.17%. For dabigatran, the percentages are 27.76%,
27.66%, and 29.21%, respectively. A similar increase is also observed in vulnerable patients with
medical history (for example, having a history of bleeding, stroke, or acquired hypothyroidism)
during the two-year period.
Table 4.2 shows the number of unadjusted incidence by trial and treatment. For the three
trials, the numbers of participants that developed any of the primary outcomes are 1,717, 2,818,
and 1,525, respectively; the numbers of participants lost to follow-up are 12,285, 15,333, and 8,850,
respectively; and the numbers of participants that reached the end of follow-up without any primary
outcome are 4,048, 10,729, and 15,392, respectively. For rivaroxaban, the average follow-ups are
273, 201, and 85 days for the three trials, respectively; For dabigatran, the average follow-ups are
255, 210, and 97 days, respectively.
Adjusted hazard ratio, temporal variation, and pooled results
As shown in Appendix Table C.4, after the IPT weighting, all sample characteristics are more
balanced between the rivaroxaban and dabigatran groups. This is further “confirmed” by Appendix
Figure C.1, which shows almost identical propensity score distributions for the weighted trial 1
cohort. Similar plots for the other two trials are omitted here.
Table 4.3 shows the adjusted hazard ratio and p-value for each outcome by trial and treatment.
For any primary outcome, rivaroxaban is found to have a significantly higher hazard ratio in all
three trials. However, the magnitudes of the estimated hazard ratio and p-values show considerable
temporal variations. There are also significant temporal variations for the two primary effectiveness
outcomes. Rivaroxaban is found to have a significant protective effect for ischemic stroke in trials 1
and 2, but non-significantly increases its risk in trial 3. To get more insight into this difference, we
show in Figure 4.2 the Kaplan-Meier survival curves of ischemic stroke outcome as an example. We
acknowledge the difference in follow-up periods for the three trials, but also note that the survival
curves for the three trials differ significantly in the early days of follow-up. As such, the observed
difference in treatment effect cannot be fully attributed to the follow-up difference. For other











































































































































































































































































































































































































































































































































































































































the estimated hazard ratio switches sign between trial 1 and the other two. For all the safety
outcomes (all-cause mortality, major bleeding, and any bleeding), rivaroxaban is observed to be
significantly inferior. Again, it is observed that the magnitudes of the estimated hazard ratios and
p-values vary across trials. For AMI, there are no significant differences between the two drugs for
all three trials.
Trial 1 Hazard Ratio (HR) p-value
Primary outcome Any primary events 1.072 0.0403
Ischemic stroke 0.799 0.0004
Other thromboembolic events 0.935 0.4892
Major bleeding 1.119 0.1280
All-cause mortality 1.252 <.0001
Secondary outcome
Any bleeding 1.413 <.0001
AMI 0.979 0.8549
Trial 2 HR P-value
Primary outcome
Any primary events 1.266 <.0001
Ischemic stroke 0.892 0.0333
Other thromboembolic events 1.133 0.1595
Major bleeding 1.237 0.0004
All-cause mortality 1.510 <.0001
Secondary outcome
Any bleeding 1.661 <.0001
AMI 0.954 0.6517
Trial 3 HR P-value
Primary outcome
Any primary events 1.380 <.0001
Ischemic stroke 1.085 0.2490
Other thromboembolic events 1.228 0.0692
Major bleeding 1.183 0.0480
All-cause mortality 1.752 <.0001
Secondary outcome
Any bleeding 1.867 <.0001
AMI 0.884 0.3699
Pooled Results HR P-value
Primary outcome
Any primary events 1.232 0.0025
Ischemic stroke 0.915 0.2819
Other thromboembolic events 1.086 0.2934
Major bleeding 1.187 <.0001
All-cause mortality 1.488 <.0001
Secondary outcome
Any bleeding 1.633 <.0001
AMI 0.944 0.3988
AMI acute myocardial infarction
Table 4.3: Adjusted hazard ratio and p-values for the primary and secondary outcomes
The pooled hazard ratio shows that, compared to dabigatran, rivaroxaban has a significantly
increased risk of any primary outcome. It non-significantly reduces the risk of ischemic stroke and
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Figure 4.2: Survival curves of time to ischemic stroke
AMI, non-significantly increases the risk of other thromboembolic events, and significantly increases
the risk of all the safety outcomes (all-cause mortality, major bleeding, and any bleeding).
4.1.5 Discussion
The effectiveness of rivaroxaban and dabigatran for AF has been well established. It is not our goal
to challenge or re-establish this conclusion. Rather, considering that both have been extensively
used in clinical practice, our goal is to conduct a direct comparison, which has been insufficiently
pursued in the literature. Without being able to conduct a real trial, we have resorted to the
emulation approach to “assemble” trials based on observational data to draw causal statements.
We note that, in terms of statistical measures (accuracy, efficiency, etc.), there is no definitive
conclusion on the performance of different causal inference techniques. The adopted emulation
approach can be preferred with more intuitive interpretations. In addition, as partly shown in this
article, it can also provide guidance to the development of a real trial (if it ever becomes feasible).
The potential limitations of emulation have been well discussed in the literature [36, 37, 104, 115]
and will not be repeated here.
We have analyzed the Medicare data, which is the most comprehensive and largest medical
record database for seniors in the U.S. Nevertheless, it has limitations. Specifically, as a medical
claims database, it does not include certain information [116]. As such, we are not able to verify if
the two treatment groups are also balanced in other potentially relevant but unmeasured aspects.
We note that this limitation is also shared by quite a few other emulation and other causal inference
studies [103,104,106,115]. Medicare has an almost universal coverage in the U.S elderly population.
As such, the findings can be applied to this population with reasonable confidence. Although there
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is no indication that the treatment effects of rivaroxaban and dabigatran depend on race and
other demographic factors, the applicability of our findings to other populations still needs further
examination. Moreover, we have had limited data access, which has led to a not current dataset, a
limited sample size, and a limited follow-up (we note that drug usage information is not available
in the “generic” Medicare database). On the other hand, we also note that there has been no
indication in the literature that the treatment effects of the two drugs differ between the study
and other periods. The sample size in this study has already been considerably larger than its
peers [101, 111, 117, 118]. In addition, there has been a considerable number of events, even in the
third trial with the shortest follow-up.
Our analysis has led to the following main findings. The first is that, based on both the indi-
vidual trials and pooled effects, dabigatran is found to be significantly superior to rivaroxaban in
terms of reducing safety concerns (bleeding events and overall mortality). This finding is consistent
with the existing observational data analyses [111,112,117,119]. As discussed in Graham [112], the
higher bleeding risk and mortality of rivaroxaban may be the side effects of the once-daily regi-
men, leading to higher peak and lower trough serum concentrations than twice-daily administrated
dabigatran. Another finding is that rivaroxaban and dabigatran are not significantly different
in preventing ischemic stroke and other thromboembolic events. In some of the existing obser-
vational studies, results are non-conclusive regarding the preventive effects of rivaroxaban versus
dabigatran [111, 112, 117–121]. This can be caused by differences in study populations and anal-
ysis techniques. As we do not have access to other data, it is impossible to exactly pin down the
causes. An interesting finding, which has been largely neglected in the literature, is the tempo-
ral variations. First, it is observed that in the study period, the prescription of rivaroxaban was
increasingly preferred over dabigatran. In trial 1, the rivaroxaban group accounts for 32.58% of
the whole study sample, whereas in trial 3, it accounts for 64.36%. Southworth et al. suggested
that this change in prescription pattern might be attributed to that post-marketing reports caused
misconceived bleeding risks with dabigatran [122]. In addition, patients initiating rivaroxaban are
slightly younger and healthier. Interestingly, some other studies have observed opposite prescrip-
tion patterns. Because rivaroxaban has been studied in older and higher-risk populations, some
physicians are more likely to prescribe rivaroxaban to high-risk elderlies [120]. Some other studies
have also found that rivaroxaban patients are older and with more comorbidities. One plausible
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explanation for the difference between this and other studies is that, our trial enrollment period
includes the early stage after rivaroxaban’s new approval, and physicians often tend to use familiar
(and seemingly safer) drugs for sicker patients (it is noted that we have focused on patients with
MCCs). This may also partly explain the increasing prescription of rivaroxaban over the two-year
period.
This study may be the first to observe that some findings on treatment effects also have temporal
variations. In the existing emulation studies, the study time periods are usually not strongly
justified, with the underlying belief (or assumption) that the findings should not depend on time
periods. As can be partly seen from the survival curves, observed differences are obvious. A
deeper examination suggests that, although there are some differences between trials in terms of
demographic and clinical characteristics, such differences are not sufficient to explain the treatment
effect differences. This analysis may raise the alarm for other emulation studies, which may also
face temporal variations.
4.1.6 Conclusion
This study has provided a direct and objective comparison of the treatment effects of rivaroxaban
and dabigatran via conducting an emulation analysis of the Medicare data. The findings may assist
clinicians making more informed decisions in the treatment of senior AF patients with MCCs. This
study also provides another demonstration of applying the emulation technique to draw causal
conclusions based on observational medical record data. Despite certain limitations, it is expected
to be informative for various stakeholders, including clinicians, patients, and biomedical/statistical
researchers.
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4.2 Evaluation of survival outcomes of endovascular versus open
aortic repair for abdominal aortic aneurysms with a big data
approach
4.2.1 Introduction
Abdominal aortic aneurysm (AAA) is a balloon-like dilatation of the aorta that supplies blood to
the body and happens below the chest. Each year, it is estimated that 200,000 people in the U.S.
are diagnosed with AAA, and ruptured AAA (rAAA) poses significant clinical and public health
challenges [123]. rAAA is associated with an overall mortality rate of over 80%, which causes more
than 5,000 deaths in the country each year [124, 125]. Once rAAA occurs, repairing procedures
need to be conducted immediately. In the current clinical practice, there are two main approaches:
emergent open aortic repair (OAR) and endovascular aortic repair (EVAR). OAR has a relatively
longer history and is still considered as the standard procedure for AAA repair, during which large
incisions are unavoidable [126]. EVAR was first successfully conducted and reported in year 1994,
and only small incisions in the groins are needed [127]. However, this circumvented procedure makes
EVAR require more intense monitoring and probable reintervention [33]. Moreover, preoperative
imaging and specific anatomic requirements make EVAR less well suitable for emergent rAAA.
As suggested in multiple studies [128–132], the preferred minimum invasion but awaited long-term
postoperative complications may account for the favorable 30-day mortality but similar or even
inferior late survival of EVAR compared to OAR. With the criticalness of rAAA and prevalence
of EVAR and OAR, it is of significant interest to objectively evaluate and directly compare their
survival outcomes.
In general, to compare the effects of two treatments, the gold-standard approach is to conduct
a randomized controlled clinical trial. However, most of the existing clinical trials have focused
on patients who have elective/intact AAA (eAAA/iAAA) and excluded those who have rAAA
and require emergent care (e.g., OVER [128], DREAM [129]). This is highly sensible as patients
with rAAA cannot bear the prolonged process of eligibility examination, treatment assignment,
and finally, surgical procedure, which are non-negligible steps in a clinical trial for bias control but
unacceptable for saving lives in a real-world setting.
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With the aforementioned concerns, researchers have focused on observational data and analysis
to investigate the survival outcomes of the two procedures for rAAA patients. Our literature
review suggests that quite a few of them have relied on large medical claims databases including
Medicare [33, 131, 133, 134]. In these studies [33, 131], regression and other association analysis
techniques have been the main tools. It is well recognized that such analyses, even after accounting
for confounders, can only lead to conclusions on association, as opposed to the desired cause-
and-effect relationship. To overcome such limitations, causal inference techniques [35, 36, 135] can
be adopted. Here we note that, with extensive examinations and comparisons, no approach has
been observed to dominate others – it is expected that such an approach may not exist, and
different approaches have different pros and cons. In this article, we adopt the emulation approach,
which is relatively new but has already been examined in many publications [38, 136, 137]. With
this approach, a clinical trial is explicitly designed and assembled using observational data, and
statistical analysis approaches designed for clinical trials can be then adopted, leading to causal
statements. Comparatively, the biggest advantage of this approach may be its lucid interpretations.
Built on the emulation strategy, we take a big data analysis approach. Here “big data” is
manifested in at least two perspectives. The first is that our effort is built on the Medicare data.
The Medicare database is massive, covers the dominating majority of the U.S. senior population,
and contains comprehensive information. Compared to for example hospital- and community-based
data, Medicare data is advantageous with its unbiased sample selection and relatively uniform and
detailed data collection. It has served as the basis of a large number of clinical and public health
studies, including those that adopt causal inference analysis techniques [38, 138]. More details on
the analyzed Medicare data are provided below in Section 4.2.2. The second big data perspective is
that in analyzing the emulated trial, deep learning techniques are adopted. In “standard” emulation
analysis (as well as most if not all analysis of real clinical trials) [38, 137], regression (e.g., logistic
and Cox) techniques have been adopted. For diverse fields including engineering, business, social
science, and others [139,140], the superiority of deep learning techniques in prediction has been well
established through a myriad of published studies. Relatively recently, deep learning techniques
have been applied to biomedical studies on cancer [141], fracture [142], chronic diseases [143],
and cardiovascular diseases [144]. The studied outcomes/phenotypes include continuous [143],
categorical [142], and, more recently, survival [145]. It is noted that the existing deep learning
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analyses of biomedical data are mostly in the association analysis domain.
The overarching goal of this study is to directly compare EVAR versus OAR for rAAA patients
and draw conclusions as close to causal as possible, so as to further inform clinical practice. This
study may advance from the existing literature in multiple aspects. First, it strives to compare
the treatment effects of EVAR and OAR under the clinical trial framework, as opposed to the
commonly adopted observational data analysis framework. Second, it advances from the existing
emulation analyses by investigating a new disease condition and treatments, which have critical
clinical importance. In addition, deep learning techniques, as opposed to “simple” regressions, are
adopted. This study may assist introducing deep learning to the emulation paradigm. Third, it
may also foster deep learning research. More specifically, this is the first application of deep learning
to the emulation analysis and study of rAAA. Built on the existing deep learning components, we
assemble an analysis pipeline that mimics the “propensity score + inverse probability treatment
– IPT weighting Cox regression” approach (which has been adopted in the existing emulation
analyses [38,137]).
Looking at a higher level, an “ordinary” clinical trial generates an information set (target),
whose most notable characteristic is the balance in information between two treatment arms. In
addition, it is usually assumed that such an information set can be sufficiently described using a
(semi)parametric model. Information contained in observational data fundamentally differs from
the target. As such, a central goal of the emulation approach is to properly carve a piece of
information, as large as possible, that mimics the target. With the deep learning analysis approach,
the (semi)parametric probabilistic structure can be significantly relaxed. Overall, this study falls
into the intersection of information theory and machine learning.
4.2.2 Methods
Data source
As briefly mentioned above, we analyze the Medicare data in this study. Medicare is a federal health
insurance program for adults aged 65 years and above, certain younger people with disabilities, and
people with end-stage renal disease (permanent kidney failure requiring dialysis or a transplant).
As the single largest payer of health care in the U.S., it covers 98% of adults who are over 65
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years old, accounts for 99% of death in the elderly population, and generates a huge amount of
medical claims data [146]. The centers for Medicare & Medicaid Services (CMS) offers a wide
range of datasets that follow Medicare beneficiaries across multiple care settings. More specifically,
it collects over two billion data points per year through reimbursement to hospital care (Medicare
Part A), physician and outpatient services (Medicare Part B), drug prescription (Medicare Part
D), and other health care claims. It also collects billions of other data points through enrollment
information, beneficiary eligibility checks, quality metrics, and calls to 1-800-MEDICARE [4].
For our study, we first retrieve all inpatient claims between 01/01/2011 to 09/30/2015 from the
Medicare provider utilization and payment data: hospital care (Part A), which contains detailed
information on health services provided in 54 million inpatient episodes for 23 million Medicare
beneficiaries. Information contained in each claim includes beneficiary demographics (e.g., age,
sex, race), Medicare enrollment status, services provided (up to 25 diagnosis codes and up to 25
procedure codes), and beneficiary death information. More details on such information and how it
is utilized in our analysis are provided below.
It is noted that for research purposes, the Medicare data can be viewed as publicly available.
We only conduct secondary analysis of the existing deidentified data. As such, no IRB or other
approvals are needed.
The target randomized clinical trial
Under the emulation analysis paradigm [37], one of the first and most important steps is the design
of a target randomized clinical trial. For treating rAAA, there is a lack of real clinical trials. As
such, similar to in some literature [38], we need to design a hypothetical target trial. The following
design has been motivated by relevant observational studies [33, 131–134] and is clinically well
grounded.
The target randomized clinical trial aims to compare the short- and long-term all-cause mortality
of rAAA patients treated with EVAR and OAR. More specifically, we enroll participants who are
diagnosed with rAAA within the enrollment period and exclude those who meet any of the following
criteria: 1) the participant is under 65 years old at enrollment; 2) conversion between EVAR and
OAR is necessary after randomization; 3) the participant has concurrent conditions of thoracic
aneurysms, thoracoabdominal aneurysms, or aortic dissection; and 4) a repair of the thoracic aorta
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or visceral or renal bypass is considered necessary for the participant. If a participant develops
multiple cases of rAAA during the enrollment period, only the first is considered as the primary
case and included in analysis. Such criteria have been motivated by observational studies [33, 132]
and data availability, and have the same level of rigor as a real clinical trial.
The trial enrolls participants from 01/01/2011 to 09/30/2015. After enrollment, each eligible
participant is randomized to receive either EVAR or OAR and followed until death, loss to follow-
up, or end of the study (06/30/2019). Such decisions have been made with the considerations that
both treatments have been extensively adopted in the study period, the enrollment is long enough
to ensure a sufficient sample size, and the follow up is long enough to ensure a sufficient effective
sample size.
To assess both short- and long-term mortality after EVAR and OAR, we define two primary
outcomes: time from treatment to short-term perioperative mortality and time from treatment to
long-term all-cause mortality. The short-term perioperative mortality is defined as death during
the index hospitalization or within 30 days of discharge, for which all participants alive at 30 days
after discharge are censored. For the long-term all-cause mortality, a subject is censored at loss to
follow-up or end of the study (06/30/2019), whichever comes first. The two survival outcomes have
different implications but are both critically important [132].
The emulated trial
To emulate the target randomized clinical trial described above, we develop an emulated trial using
the Medicare claims data. The strategy closely follows that developed in the emulation literature
[38]. First, we identify Medicare beneficiaries who were diagnosed with rAAA and underwent EVAR
or OAR between 01/01/2011 and 09/30/2015. We exclude individuals that met any of the following
criteria: 1) the individual was under 65 years old at diagnosis; 2) both EVAR and OAR were present
in the same index hospitalization, which indicated conversion; 3) concurrent diagnosis codes of
thoracic aneurysms, thoracoabdominal aneurysms, or aortic dissection; 4) concurrent procedure
codes of repair of the thoracic aorta or visceral or renal bypass; and 5) less than 12 months of
Medicare enrollment before the index hospitalization. If a beneficiary had multiple eligible claims,
only the first was considered as the primary case and included in analysis. Additional information on
patient selection is provided in the flowchart in Figure 4.3. The relevant International Classification
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of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes are provided in Appendix
Table C.5.
Figure 4.3: Flowchart of cohort definition
We then classify each eligible subject into one of the two treatment groups: EVAR and OAR,
based on the procedure he/she actually received. Follow-up information is then extracted for each
subject (to death, loss to follow-up, or end of the study which is 06/30/2019). A loss to follow-up
is defined as discontinuation of Medicare enrollment. To identify the primary outcomes, we track
each study subject from treatment to his/her documented death. We note that there are 5.35%
study subjects for whom the date of treatment is missing. For these subjects, we use the date of
admission to approximate the date of treatment, since rAAA is an emergent condition that needs




This study has survival outcomes. If this were a real clinical trial, analysis could be conducted
using a Cox model. Although balance is expected with proper randomization, to be cautious, in
clinical trial analysis, potential confounders are still commonly adjusted. For an emulated trial
with a survival outcome, published studies [38, 137] suggest the following main analysis steps: (a)
conduct a propensity score analysis for treatment using the logistic regression approach, and (b)
conduct a Cox regression analysis for survival with inverse probability treatment – IPT weighting.
As briefly mentioned in Section 4.2.1, deep learning has demonstrated promising performance
with biomedical data. It is of significant interest to apply it to emulation. Equally importantly,
the analysis presented in the Appendix C.2.2 shows that the Cox proportionality assumption is
not satisfied. The deep learning approach described below, although has some connections with
the Cox model, can be more flexible and less dependent on model assumptions, with its “built-in”
flexibility. It consists of the following steps: (a) generate propensity scores for treatment using
a single-layer neural network. This corresponds to the logistic regression mentioned above; (b)
construct a multi-layer neural network for survival. Advancing from the “standard” deep learning
survival, we incorporate weights generated in Step (a), which corresponds to the IPT weighted Cox
regression mentioned above; and (c) advancing from the existing deep learning literature, we also
conduct a bootstrap-type procedure to gain insights into the variation of the neural network weight
estimation, which is analogous to the regression coefficient estimation and reveals the treatment
effects.
Denote n as the number of independent subjects. For subject i, denote Ci as the censoring
time and Ti as the event time. We observe the right-censored survival outcome Yi = min(Ti, Ci)
and censoring indicator di = I(Ti ≤ Ci) with I(·) being the indicator function. Denote Xi =
(Xi1, Xi2, ..., Xip) as the baseline covariates and Zi as the binary treatment assignment.
Step 1: We employ a single-layer neural network to estimate the propensity score, which
is the probability of treatment assignment conditional on the baseline covariates. In particular,
the input includes the covariates described in Table 4.4, with standardization for the continuous
variables and coding for the categorical variables. The labels in the data are the binary treatment





Age, mean(sd) 78.03 (7.52) 76.59 (6.90) <.0001
Male 3023 (76.34) 2786 (72.06) <.0001
Race 0.0030
White 3588 (90.77) 3550 (92.02)
Black 249 (6.30) 178 (4.61)
Other 116 (2.93) 130 (3.37)
Medical conditions
Congestive heart failure 464 (11.72) 299 (7.73) <.0001
Cardiac arrhythmia 596 (15.05) 438 (11.33) <.0001
Valvular disease 199 (5.03) 172 (4.45) 0.2304
Coronary disease 758 (19.14) 603 (15.60) <.0001
Diabetes 329 (8.31) 256 (6.62) 0.0045
Hypertension 1250 (31.25) 1078 (27.88) 0.0004
Chronic obstructive pulmonary diseases 707 (17.85) 584 (15.11) 0.0011
Clinically significant lower extremity vascular diseases 26 (0.66) 27 (0.70) 0.8215
Renal atherosclerosis 20 (0.51) 27 (0.70) 0.2684
Vascular intestine disease 7 (0.18) 2 (0.05) 0.1027
Renal failure 493 (12.45) 358 (9.26) <.0001
Other renal diseases 3 (0.08) 1 (0.03) 0.3289
Kidney transplant 4 (0.10) 3 (0.08) 0.7291
Liver disease 33 (0.83) 30 (0.78) 0.7766
Cerebrovascular diseases and paralysis 93 (2.35) 67 (1.73) 0.0544
Other neurological diseases 153 (3.86) 114 (2.95) 0.0258
Hyperlipidemia 817 (20.63) 687 (17.77) 0.0013
Cancer 132 (3.33) 87 (2.25) 0.0037
Rheumatoid arthritis 76 (1.92) 39 (1.01) 0.0008
Prior intact AAA diagnosis 511 (12.90) 440 (11.38) 0.0393
Other
Year in which repair was performed <.0001
2011 808 (20.40) 1013 (26.20)
2012 869 (21.94) 913 (23.62)
2013 819 (20.68) 785 (20.31)
2014 837 (21.14) 701 (18.13)
2015 627 (15.83) 454 (11.74)
Outcome (followed until death, loss to follow-up, or 06/30/2019)
All-cause mortality 2430 (61.36) 2542 (65.75) <.0001
Perioperative mortality (in-hospital or 30 days after dis-
charge)
1107 (27.95) 1704 (44.08) <.0001
* P-values are based on t-tests for continuous variables and Chi-squared test for categorical variables
Table 4.4: Descriptive characteristics of the study cohort
as the activation function, sigmoid activation function to produce the probability output, and
logarithmic loss function (binary cross-entropy). For optimization, a stochastic gradient descent
algorithm with Nesterov momentum is used, and a grid search is conducted to tune the learning
rate. For such tasks, we adopt the open-source python module keras (https://keras.io). With the
outputted propensity score, we compute the IPT weight as its inverse for a subject in one treatment
group and the inverse of one minus propensity score for a subject in the other group.
Step 2: Here we conduct the IPT weighted survival analysis. The input includes the same set
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of covariates and treatment indicator as in Step 1, as well as the IPT weights computed above. For
subject i, denote wi as the IPT weight and Ri = j : Tj > Ti as the at-risk set (at time Ti). We
consider a neural network with two hidden layers and the number of nodes determined by tuning.
Denote θ as the weights that characterize the network (note that they are not the IPT weights),
and gθ(Xi, Zi) as the output for subject i. Partly motivated by the loss function under the Cox
regression as well as recent deep learning studies, such as DeepSurv, we consider the objective
function:








For optimization, we adopt a gradient descent approach. ReLU is used as the activation func-
tion, and the adaptive moment estimation algorithm (Adam) for gradient descent optimization
with a cyclical learning rate method is adopted. We perform a grid search for hyper-parameter
tuning. The computational program is developed based on the open-source python module pycox
(https://github.com/havakv/pycox ).
Step 3: A procedure similar to the 0.632 bootstrap for regression analysis [147] is conducted.
In particular, 0.632n samples are randomly selected from the original data without replacement.
With the bootstrapped samples, the above analysis is conducted, and the neural network weight
estimates are extracted. This is repeated multiple (e.g. 1,000) times to assess the variability of
estimates. For regression, the 0.632 bootstrap is equivalent to the “n-out-of-n with replacement”
bootstrap. By sampling without replacement, it can reduce ties and computational cost.
The above analysis can deliver the following. The first is a propensity score estimate for each
subject. If needed, the weights of the neural network can be extracted to help assess the relative
contributions of covariates. The second is the survival neural network. For a subject with a set
of known confounder values and treatment assignment, it can generate the (relative) survival risk.
Most of the existing deep learning studies have treated neural networks as black boxes. As we
conduct a clinical trial analysis, the effect of the treatment is of the most essential interest. As
such, we retrieve the estimated weights for the treatment indicator and confounders. With the
presence of hidden layers, the weight matrices need to be multiplied across layers to obtain the
overall contributions. The third product is that, for the (overall) weight of the treatment indicator,
the bootstrap-type analysis can generate an evaluation of its variability. The same is also applicable
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to the confounders.
Remarks For binary responses, the superiority of neural networks over logistic and other
regressions has been demonstrated in a large number of publications [141,142]. Several recent pub-
lications, such as DeepSurv [145] and Cox-nnet [148] and others, seem to suggest similar superiority
for survival data. As our goal is to take advantage of the recent deep learning developments, we
choose not to “re-establish” the merit of deep learning. We also note that there are multiple “base
techniques” for building neural networks. The adopted ones have been shown in recent studies as
having competitive performance. To the best of our knowledge, there is still no study showing that
certain techniques dominate the others.
4.2.3 Results
Patient characteristics and unadjusted incidences
Our analysis includes 7,826 eligible subjects, with 3,960 in the EVAR arm and 3,866 in the OAR
arm. The summary statistics are shown in Table 4.4. It is observed that the study subjects were
slightly younger in the OAR arm, and more likely to be white males in both arms. Participants
in the OAR arm were healthier with lower percentages of almost all medical conditions (except for
two rare conditions: clinically significant lower extremity vascular diseases and renal atheroscle-
rosis). It is also observed that, as time passed by (from year 2011 to 2015), the rAAA patients
were more and more likely to receive EVAR. Here we note that, without the IPT weighting, all
demographic variables and most medical condition variables are significantly unbalanced between
the two treatment arms, highlighting a significant difference between real clinical trials and obser-
vational data. Table 4.4 also shows the unadjusted incidence rates by treatment. The EVAR arm
has a slightly lower unadjusted incidence rate for long-term all-cause mortality and a significantly
lower unadjusted incidence rate for short-term perioperative mortality.
Analysis of the emulated trial
Prior to analysis, we delete 15 records with missing measurements (7 in the EVAR arm and 8
in the OAR arm). Analysis is conducted using the approach described in Section 4.2.2. For the
propensity score analysis, the baseline covariates include age, gender, race, year in which repair
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was performed (this variable has been considered in the published observational studies [33,131]; it
is also motivated by the changing rates of EVAR and OAR), and 20 medical conditions, as shown
in Table 4.4 (related ICD-9-CM codes in Appendix Table C.5). For survival analysis, the same
baseline covariates and treatment indicator are included.
For both the propensity score and survival analysis, the obtained fully connected neural network
architectures are available from the authors. For the propensity score analysis, the learning rate is
tuned as 0.008. The distributions of propensity scores are shown in Figure 4.4. Minor differences
between the two arms are observed.
Figure 4.4: Distribution of propensity score
For the analysis of short-term survival, the learning rate for Adam optimizer is tuned as 0.016.
The analysis results are summarized in Figure 4.5. The left panel shows the estimated survival
curves, after accounting for IPT weights, for the two treatments separately. With the bootstrap
procedure, we are also able to obtain the pointwise 90% confidence intervals. It is noted that
this analysis mimics the “familiar” regression analysis and differs from most of the existing deep
learning studies. EVAR is observed to have a modest survival advantage, with the lower bounds
of its confidence intervals almost coinciding with the upper bounds of OAR’s confidence intervals.
Based on the estimated survival curves, we compute the expected survival under EVAR as 83.5 days,
compared to 79.2 days under OAR. In the right panel of Figure 4.5, the forest plot, which shows the
medians as well as the 25% and 75% quantile values of the overall estimated weights (“accumulated”
over layers), again suggests the survival advantage of EVAR. The right panel of Figure 4.5 also
contains weight information for confounders that demonstrate considerable and “persistent” effects
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(across the bootstrapped datasets), including race and seven medical conditions.
Figure 4.5: Analysis of short-term mortality (left: estimated survival curves with pointwise 90%
confidence intervals; right: forest plot of the estimated weights)
For the analysis of long-term survival, the learning rate for Adam optimizer is tuned as 0.036.
The analysis results are summarized in Figure 4.6, which are parallel to those in Figure 4.5. The
findings are similar to those for short-term survival. Briefly, the left panel suggests some advantage
of EVAR, but the pointwise confidence intervals overlap. We compute the expected survival as
1464.2 days under EVAR and 1348.0 days under OAR. The forest plot in the right panel shows that
the advantage of EVAR is smaller than that for short-term survival. Confounders that demonstrate
considerable and “persistent” effects include race, sex, and six medical conditions.
Figure 4.6: Analysis of long-term mortality (left: estimated survival curves with pointwise 90%
confidence intervals; right: forest plot of the estimated weights)
Remarks For comprehensiveness, we also conduct regression-based analysis. The results are
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presented in Appendix C.2.2. As the Cox model assumption is violated in both survival analyses,
the results cannot be sensibly utilized.
4.2.4 Discussion
As fully discussed in the published literature, the Medicare data has multiple unique advantages.
With its broad coverage of the U.S. elderly population, our findings can be applied to this population
with high confidence. Although there is no evidence that the relative treatment effects of EVAR
and OAR differ by age, sex, and race [132–134], application of the findings to the younger U.S.
population and populations in other countries/regions should be conducted with cautions. On the
other hand, it has also been recognized that the Medicare data has limitations [4,146]. For example,
it does not contain certain information (e.g., over-the-counter drug use). As such, there may exist
imbalance on unmeasured confounders. We note that this limitation is shared by other emulation
studies and analysis of observational data. We have analyzed the Medicare inpatient data from
01/01/2011 to 06/30/2019. Both the enrollment and follow-up times are long enough, especially
compared to peer studies [132–134]. Although there is no indication that the treatment effects
have temporal variations, it may still be of interest to examine more extensive data (which is not
pursued with data access limitations). Another data limitation is that we do not have access to
data on other clinical settings (e.g., emergency room or outpatient). With the special nature of
rAAA, inpatient claims should be able to catch the dominating majority of the cases.
The emulation strategy has been developed and adopted in quite a few studies. Its pros and
cons have been well documented [36, 38, 137]. It is especially noted that, first, emulation trials,
although resembling real clinical trials in multiple perspectives, still have notable limitations and
cannot replace real clinical trials. Second, there is still a lack of objective comparison and definitive
conclusion on its relative performance with respect to other causal inference approaches. Although
important, this is beyond the scope of this study. The adopted deep learning methods have been
based on certain well-developed components and software programs. Nevertheless, their “combi-
nation” and application to the emulation setting and rAAA treatment problem are new and novel.
Our analysis has demonstrated how to “replace” regression using deep learning under settings more
sophisticated than in the literature. As the “propensity score + survival analysis” strategy and indi-
vidual components of the deep learning analysis have been more or less developed in the literature,
90
we choose not to methodologically further discuss or conduct more numerical investigations.
Our main finding is that EVAR has advantageous short- and long-term survival. Although the
improvement in expected survival is modest, considering the severity of rAAA, it may still have
important clinical implications. In the literature, the short-term survival advantage of EVAR has
been suggested in multiple observational analyses [33, 131, 133]. However, there has been a lack of
definitive conclusion on the long-term benefit. For example, Behrendt et al. [132] suggested early
survival benefit of EVAR over OAR, which reversed at ∼2.5 years of follow-up, for iAAA and rAAA
patients in Germany. Schermerborn et al. [33] observed similar survival of the two procedures after
3 years from initial surgery for iAAA patients in the Medicare population. And a 15-year follow-
up resulted from the EVAR-1 trial indicated that EVAR had inferior late survival compared with
OAR [130]. Multiple factors can contribute to the differences observed in the aforementioned and
other studies. First, the studied populations have different characteristics. Second, the analysis
strategies also differ, with our strategy closer to a controlled clinical trial. It is also noted that the
study periods are different. Although there is still no indication of temporal variation in treatment
effects, related confounders may change over time.
Besides treatment, our analysis also suggests that race, gender, and certain medical conditions
are associated with survival after EVAR and OAR among rAAA patients. While most observational
studies that compare EVAR and OAR match study subjects or adjust for potential confounders,
there is a lack of attention on how these variables may impact survival after rAAA. We have
found that compared to other races, the white race is associated with lower short- and long-term
mortality, and the black race is associated with lower short-term mortality. This race difference
has been insufficiently studied in the literature. It can be caused by genetic effects (considering
that genetic factors contribute to many cardiovascular diseases), lifestyle, cultural factors, access to
care, and other factors that may confound survival. While Egorova et al. [133] observed significantly
worse outcomes after EVAR and OAR for female patients, we have found no gender difference in
short-term mortality and male associated with higher long-term mortality. One contributing factor
is the difference in analysis technique: Egorova et al. [133] compared the observed survival with
expected survival in a life table, while we have conducted a more comprehensive adjusted analysis.
Lastly, we have identified certain medical conditions as associated with survival. What may seem
counterintuitive is that some medical conditions are found as negatively associated with mortality.
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For example, it is found that prior iAAA diagnosis decreases short-term mortality risk after rAAA,
and the presence of cardiac arrhythmia increases both short- and long-term survival. One plausible
explanation is that patients with related medical conditions are more likely to have regular hospital
visits and more access to healthcare services, which may lead to more timely detection of emergent
rAAA. For example, it is noted in Edwards et al. [131] that patients who had a prior diagnosis of
iAAA were less commonly admitted through the emergency department, and were more commonly
transferred between hospitals before treatment, which was associated with better survival. Dardik
et al. [149] also found that the presence of hypertension, diabetes, and COPD were correlated with
a statistically significant lower mortality rate, whereas the presences of smoking, heart disease,
and renal disease were correlated with a statistically insignificant lower mortality rate after the
diagnosis of rAAA.
4.2.5 Conclusion
This study has suggested certain short- and long-term survival advantage of EVAR over OAR
for rAAA patients. It has also further advanced the emulation and deep learning techniques for
analyzing data mined from large medical record databases. Both the medical findings and analytic





With the Medicare administrative data, this dissertation develops various statistical methods for
biomedical research in older adults. Chapter 2 and Chapter 3 focus on examining disease intercon-
nections in healthcare outcome measures using network analysis. To be more specific, in Chapter
2, we build a clinical treatment HDN on inpatient LOS. Considering that multiple outcomes are
closely related to each other, In Chapter 3, we build a clinical treatment HDN that can incorporate
multiple variables. We analyze LOS and readmission data in Chapter 3 and note that the proposed
method can be easily expanded to incorporate more outcomes of different data types. In both
chapters, to accommodate uniquely challenging data distributions (high-dimensionality and zero-
inflation), novel modeling and estimation approaches have been developed. The methodological
developments may have other applications and can foster complex network analysis. Based on the
constructed networks, we analyze key network properties such as connectivity, module/hub, and
temporal variation. The findings are found to be largely supported by existing biomedical evidence.
A closer examination of analysis results also reveals novel findings that are less/not investigated
in the individual-disease studies. These findings have clinical importance and can provide valuable
information in guiding future analysis. The proposed clinical treatment HDNs complement existing
molecular and phenotypic HDNs by being more clinically sensible and having more practical impli-
cations. They can be used to guide more efficient allocation of hospital beds and other resources,
provide additional insights into disease interconnections from a treatment perspective, and define
an alternative way of disease characterization and classification.
In Chapter 4, we adopt the emulation approach to conduct causal inferences on treatment/intervention
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effects. With emulation analysis, we first compare rivaroxaban and dabigatran’s effectiveness and
safety outcomes for Medicare patients with atrial fibrillation. We analyze the emulated trial using
propensity score and IPT weighting Cox proportional hazards regression. We find that dabigatran
is superior in terms of time to any primary event (including ischemic stroke, other thromboembolic
events, major bleeding, and death), major bleeding, and mortality. Differences between the two
drugs in terms of stroke and other thromboembolic events are not significant. We also observe tem-
poral variations, which have been largely neglected in other emulation studies. Considering that
the regression-based statistical techniques generally have too strict data assumptions (e.g., Cox
proportional model for survival data), we develop a novel deep learning strategy, which mimics the
“propensity score + IPT weighting Cox regression” approach. We note that the proposed method
can be easily generalized to other regression models and data types. We apply this approach to
study survival outcomes of endovascular repair versus open aortic repair for Medicare patients with
abdominal aortic aneurysms. We find that endovascular repair has survival advantages in both
short- and long-term mortality. Overall, the developed “emulation + deep learning” approach
provides an alternative and more flexible way of evaluating treatment/intervention effects using
observational data. This study is the first application of deep learning to the emulation analysis,
which can further analysis in both domains. It also showcases a new way of analyzing the scaled
and comprehensive Medicare database. The emulated trials can guide the development of a real
clinical trial (if it ever becomes feasible). The findings provide solid evidence for guiding better
clinical decisions.
5.1 Limitation
This dissertation inevitably has limitations. Due to limited data accessibility, the analyses focus on
Medicare inpatient claims. Inpatient treatment is only part of the healthcare system for Medicare
beneficiaries. Many treatments are accomplished in other clinical settings, such as outpatient office
visits and ED visits. Moreover, chronic diseases generally do not involve many hospital treatments
and are often handled with drug refillings. Nevertheless, we note that inpatient treatment is the
most serious type of treatment that consumes the most medical resources. Accordingly, analysis
focus on inpatient treatment has its unique value. We have considered the whole Medicare popu-
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lation. With the broad coverage of Medicare to the U.S. elderly population, our findings can be
applied to this population with high confidence. It will be of interest to conduct stratified analysis
to better accommodate heterogeneity. Although there is no evidence that the findings differ be-
tween race and other demographic factors, the generalization of our findings to other populations
still needs further examination.
For Chapter 2 and Chapter 3, as in many other HDN analysis, our analysis can only infer as-
sociations (with undirected networks). Causal analysis would demand significant additional data.
Besides, unadjusted outcomes are used to construct the proposed clinical treatment HDNs. It is
noted that the proposed approach in Chapter 3 is regression-based and can be expanded to include
covariants such as demographic and other risk factors. However, building HDNs on risk-adjusted
outcomes is beyond the scope of this dissertation and will be postponed to future studies. In the
analysis, we examine the temporal variations in a cross-sectional manner. Given that we have
observed significant dynamics in network structures across time, it will be of interest to develop a
time-varying network framework. This framework will require extensive new methodology develop-
ment. Moreover, the presented graphical algorithms deal with a large sample size, a large number
of unknown parameters, and a complex model structure. As a result, computation is expensive.
Luckily, estimation for each node and under different tunings can be run parallel to reduce computer
time. For larger data, further parallelization may be needed to make the analysis affordable. Our
examination suggests that the findings are biomedically sensible to a large extent. However, we are
unable to examine all findings considering a large number of diseases and interconnections. It will
also be of interest to examine additional data and provide more interpretations of the findings.
For Chapter 4, it is noted that even with full access to different treatment settings, the Medicare
database covers limited information [4,146]. For example, it does not contain information on over-
the-counter drug uses, patients’ socioeconomic status, and adherence to medication regimen, all
of which are essential confounders for treatment effects. It is unknown that whether treatment
arms are imbalanced on these unmeasured confounders. In addition to data limitations, it is
well documented in the literature that the emulation approach, while being lucidly interpretable,
has notable limitations [36, 38, 137]. For example, it can only emulate target trials without blind
assignment. There is still a lack of direct and objective comparison of this approach concerning
other causal inference approaches. It will be of interest to conduct such a comparison, but it is
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beyond the scope of this study. In the analysis, we develop an innovative deep learning approach
to mimic the commonly used “propensity score + IPT weighting Cox proportional hazards model.”
Although we conduct a bootstrap-like procedure to gain insights into the variability of estimates,
the rigorous statistical inference has not been pursued. Noting that statistical properties for neural
networks are less investigated in the literature, it will be of future interest to research more along
this direction.
5.2 Future study
With the possibility of more comprehensive data, we will expand the analysis scope to incorporate
other treatment settings and other outcomes of different data distributions. This includes accom-
modating more outcome measures in constructing clinical treatment HDNs and investigating more
medical conditional and treatments using the “emulation + deep learning” analysis approach. It
is also of future interest to validate the findings of this dissertation by examining potential un-
measured risk factors. Regarding the analysis of clinical treatment HDNs, we plan to develop
new modeling approaches, which could accommodate risk-adjusted outcomes, intervention/shock
effects, and time-dependent variables. Regarding the emulation analysis, we will conduct a direct
comparison for its relative performance concerning other causal inference techniques. We are also
planning to expand the deep learning algorithm to different data types beyond survival analysis
and derive corresponding theoretical properties.
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Appendix A
Supplementary Materials for Chapter
2
A.1 Clinical Classifications Software disease categories
Table A.1: CCS disease categories
ccs100 Acute myocardial infarction
ccs101 Coronary atherosclerosis and other heart disease
ccs103 Pulmonary heart disease
ccs104 Other and ill-defined heart disease
ccs105 Conduction disorders
ccs106 Cardiac dysrhythmias
ccs107 Cardiac arrest and ventricular fibrillation
ccs108 Congestive heart failure; nonhypertensive
ccs109 Acute cerebrovascular disease
ccs110 Occlusion or stenosis of precerebral arteries
ccs111 Other and ill-defined cerebrovascular disease
ccs112 Transient cerebral ischemia
ccs113 Late effects of cerebrovascular disease
ccs114 Peripheral and visceral atherosclerosis
ccs115 Aortic; peripheral; and visceral artery aneurysms
ccs117 Other circulatory disease
ccs118 Phlebitis; thrombophlebitis and thromboembolism
ccs120 Hemorrhoids
ccs121 Other diseases of veins and lymphatics
ccs122 Pneumonia (except that caused by tuberculosis or sexually transmitted disease)
ccs125 Acute bronchitis
ccs126 Other upper respiratory infections
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ccs127 Chronic obstructive pulmonary disease and bronchiectasis
ccs128 Asthma
ccs129 Aspiration pneumonitis; food/vomitus
ccs130 Pleurisy; pneumothorax; pulmonary collapse
ccs131 Respiratory failure; insufficiency; arrest (adult)
ccs133 Other lower respiratory disease
ccs134 Other upper respiratory disease
ccs135 Intestinal infection
ccs138 Esophageal disorders
ccs139 Gastroduodenal ulcer (except hemorrhage)
ccs140 Gastritis and duodenitis
ccs141 Other disorders of stomach and duodenum
ccs143 Abdominal hernia
ccs145 Intestinal obstruction without hernia
ccs146 Diverticulosis and diverticulitis
ccs149 Biliary tract disease
ccs151 Other liver diseases
ccs152 Pancreatic disorders (not diabetes)
ccs153 Gastrointestinal hemorrhage
ccs154 Noninfectious gastroenteritis
ccs155 Other gastrointestinal disorders
ccs157 Acute and unspecified renal failure
ccs158 Chronic kidney disease
ccs159 Urinary tract infections
ccs160 Calculus of urinary tract
ccs161 Other diseases of kidney and ureters
ccs162 Other diseases of bladder and urethra
ccs163 Genitourinary symptoms and ill-defined conditions
ccs164 Hyperplasia of prostate
ccs19 Cancer of bronchus; lung
ccs197 Skin and subcutaneous tissue infections
ccs198 Other inflammatory condition of skin
ccs199 Chronic ulcer of skin
ccs2 Septicemia (except in labor)
ccs201 Infective arthritis and osteomyelitis (except that caused by tuberculosis or sexually transmitted disease)
ccs202 Rheumatoid arthritis and related disease
ccs203 Osteoarthritis
ccs204 Other non-traumatic joint disorders
ccs205 Spondylosis; intervertebral disc disorders; other back problems
ccs206 Osteoporosis
ccs207 Pathological fracture
ccs209 Other acquired deformities
ccs211 Other connective tissue disease
ccs212 Other bone disease and musculoskeletal deformities
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ccs238 Complications of surgical procedures or medical care
ccs259 Residual codes; unclassified
ccs29 Cancer of prostate
ccs3 Bacterial infection; unspecified site
ccs4 Mycoses
ccs42 Secondary malignancies
ccs44 Neoplasms of unspecified nature or uncertain behavior
ccs47 Other and unspecified benign neoplasm
ccs48 Thyroid disorders
ccs49 Diabetes mellitus without complication
ccs50 Diabetes mellitus with complications
ccs51 Other endocrine disorders
ccs52 Nutritional deficiencies
ccs53 Disorders of lipid metabolism
ccs54 Gout and other crystal arthropathies
ccs55 Fluid and electrolyte disorders
ccs58 Other nutritional; endocrine; and metabolic disorders
ccs59 Deficiency and other anemia
ccs60 Acute posthemorrhagic anemia
ccs62 Coagulation and hemorrhagic disorders
ccs63 Diseases of white blood cells
ccs651 Anxiety disorders
ccs653 Delirium dementia and amnestic and other cognitive disorders
ccs657 Mood disorders
ccs659 Schizophrenia and other psychotic disorders
ccs660 Alcohol-related disorders
ccs661 Substance-related disorders
ccs663 Screening and history of mental health and substance abuse codes
ccs7 Viral infection
ccs79 Parkinson‘s disease
ccs81 Other hereditary and degenerative nervous system conditions
ccs82 Paralysis
ccs83 Epilepsy; convulsions
ccs87 Retinal detachments; defects; vascular occlusion; and retinopathy
ccs88 Glaucoma
ccs89 Blindness and vision defects
ccs94 Other ear and sense organ disorders
ccs95 Other nervous system disorders
ccs96 Heart valve disorders
ccs97 Peri-; endo-; and myocarditis; cardiomyopathy (except that caused by tuberculosis or sexually transmitted
disease)
ccs98 Essential hypertension
ccs99 Hypertension with complications and secondary hypertension
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A.2 Year-specific LOS HDNs
(a) 2008 (b) 2009
(c) 2010 (d) 2011
Figure A.1: Year-specific LOS HDNs
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(e) 2012 (f) 2013
(g) 2014 (h) 2015
Figure A.1: Year-specific LOS HDNs
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(i) 2016 (j) 2017
(k) 2018
Figure A.1: Year-specific LOS HDNs
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A.3 Alternative analysis
As briefly discussed in Chapter 2, the interconnections in LOS among diseases differ from those
obtained based on genetic and phenotypic information. To more firmly establish such differences
and gain additional insights into the proposed analysis, we further analyze and compare with the
molecular HDN (as developed in Goh et al. [24]) and phenotypic HDN (as developed in Hidalgo et
al. [27]).
A.3.1 The molecular HDN
This HDN is gene-centric, under which two diseases are interconnected if they share common genetic
risk factors. We note that the disease list investigated in Goh et al. [24] differs from that in this
study. To make the results more directly comparable, we need to re-do the analysis using the
approach in Goh et al. [24] but with a different list of diseases. More specifically, we first extract
data from https://phewascatalog.org/phewas [150], which contains information on shared genes
between the electronic health record driven Phenome-wide association studies codes (PheCode).
Like the CCS used in our study, PheCode is also a disease classification software that groups the
International Classification of Diseases (ICD) codes. Based on common ICD codes, we convert the
1,723 PheCodes into 204 CCS codes. We further focus on the network for the same 108 CCS codes
as in our analysis.
A.3.2 The phenotypic HDN
Hidalgo et al. [27] introduced two comorbidity measures to quantify the correlation between two
diseases. Here we adopt the φ-correlation, which is Pearson’s correlation for binary variables.
Specifically, the φ-correlation between disease i and j is defined as:
φij =
Cij − PiPj√
PiPj(N − Pi)(N − Pj)
,
where N is the total number of study subjects, Cij is the number of subjects diagnosed with both
diseases, and Pi and Pj are numbers of subjects diagnosed with disease i and disease j, respectively.
Then using the same inpatient Medicare data from January 2008 to December 2018, we construct
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the phenotypic HDN for the same 108 CCS diseases.
A.3.3 Results
Similar to the proposed LOS HDN, the molecular HDN and phenotypic HDN constructed here are
also unweighted and undirected. The obtained network structures as shown in Figure A.2, which
also includes the one constructed in Chapter 2 for comparison. The molecular HDN has 1,344 edges
and 5 modules, and the phenotypic HDN has 1,059 edges and 9 modules. In comparison, the one
constructed in Chapter 2 has 1,049 edges and 11 modules. A closer examination confirms that the
three networks are significantly different.
Figure A.2: HDNs constructed using three different approaches
Connectivity Table A.2 shows the top 10 diseases with the highest connectivity values. It is observed
that CCS58 and CCS95 are the only two diseases that are in the top 10 list for all three networks.
For the molecular HDN, the top 10 list is enriched with endocrine, metabolic, and nervous diseases.
The phenotypic HDN and LOS HDN are more similar and share seven common diseases (CCS55,
CCS59, CCS95, CCS108, CCS157, CCS58, and CCS99). Considering that molecular information
is “farther away” from clinics, the observed results are sensible and further establish the necessity
of additional analysis beyond the molecular HDN.
Module We further examine differences in module structures. Specifically, if two diseases are in the
same module under the LOS HDN but not under an alternative network, we say that their disease
module relationship is different (across networks). Comparing the LOS HDN with the molecular
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HDN CCS Disease Connectivity
Molecular ccs205 Spondylosis; intervertebral disc disorders; other back problems 82
ccs58 Other nutritional; endocrine; and metabolic disorders 82
ccs211 Other connective tissue disease 77
ccs95 Other nervous system disorders 75
ccs47 Other and unspecified benign neoplasm 73
ccs51 Other endocrine disorders 67
ccs204 Other non-traumatic joint disorders 66
ccs87 Retinal detachments; defects; vascular occlusion; and retinopathy 66
ccs59 Deficiency and other anemia 65
ccs198 Other inflammatory condition of skin 64
Phenotypic ccs59 Deficiency and other anemia 66
ccs55 Fluid and electrolyte disorders 58
ccs95 Other nervous system disorders 57
ccs157 Acute and unspecified renal failure 54
ccs99 Hypertension with complications and secondary hypertension 54
ccs159 Urinary tract infections 51
ccs131 Respiratory failure; insufficiency; arrest (adult) 50
ccs58 Other nutritional; endocrine; and metabolic disorders 49
ccs3 Bacterial infection; unspecified site 47
ccs108 Congestive heart failure; nonhypertensive 46
LOS ccs55 Fluid and electrolyte disorders 75
ccs59 Deficiency and other anemia 67
ccs98 Essential hypertension 63
ccs53 Disorders of lipid metabolism 63
ccs95 Other nervous system disorders 56
ccs108 Congestive heart failure; nonhypertensive 48
ccs157 Acute and unspecified renal failure 46
ccs58 Other nutritional; endocrine; and metabolic disorders 45
ccs138 Esophageal disorders 45
ccs99 Hypertension with complications and secondary hypertension 42
Table A.2: Top 10 diseases with the highest connectivity
HDN shows that 23.5% of the 5,778 pairwise module relationships are different. Comparing the
LOS HDN with the phenotypic HDN shows that 14.36% of the pairwise module relationships
are different. As a representative example, Figure A.3 shows the modules that other nutritional;
endocrine; and metabolic disorders (CCS58) belongs to in the three networks. It is noted that
CCS58 has relatively higher significance as it is one of the two diseases that appear in the top
10 connectivity list for all three networks. Figure A.3 shows that the three modules are highly
different. The modules under the molecular HDN and phenotypic HDN do not share any common
diseases other than CCS58. The modules under the molecular HDN and LOS HDN share two
common diseases (CCS118 and CCS135) other than CCS58. The modules under the phenotypic
HDN and LOS HDN share one common disease (CCS98) other than CCS58. In Figure A.3, shared
diseases are colored in green, and different diseases are colored in orange.
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Figure A.3: Modules that contain CCS58
A.3.4 Remarks
This analysis further supports our argument that the proposed disease interconnection analysis is
warranted beyond the existing molecular and phenotypic HDNs. It can be of interest to further ex-
plore differences and consolidate the three networks. However, that demands significant additional
research and will be postponed to the future.
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B.1 Clinical Classifications Software disease categories
Table B.1: CCS disease categories
ccs100 Acute myocardial infarction
ccs101 Coronary atherosclerosis and other heart disease
ccs103 Pulmonary heart disease
ccs104 Other and ill-defined heart disease
ccs105 Conduction disorders
ccs106 Cardiac dysrhythmias
ccs107 Cardiac arrest and ventricular fibrillation
ccs108 Congestive heart failure; nonhypertensive
ccs110 Occlusion or stenosis of precerebral arteries
ccs111 Other and ill-defined cerebrovascular disease
ccs112 Transient cerebral ischemia
ccs113 Late effects of cerebrovascular disease
ccs114 Peripheral and visceral atherosclerosis
ccs115 Aortic; peripheral; and visceral artery aneurysms
ccs117 Other circulatory disease
ccs118 Phlebitis; thrombophlebitis and thromboembolism
ccs120 Hemorrhoids
ccs121 Other diseases of veins and lymphatics
ccs122 Pneumonia (except that caused by tuberculosis or sexually transmitted disease)
ccs125 Acute bronchitis
ccs126 Other upper respiratory infections
ccs127 Chronic obstructive pulmonary disease and bronchiectasis
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ccs128 Asthma
ccs129 Aspiration pneumonitis; food/vomitus
ccs130 Pleurisy; pneumothorax; pulmonary collapse
ccs131 Respiratory failure; insufficiency; arrest (adult)
ccs133 Other lower respiratory disease
ccs134 Other upper respiratory disease
ccs135 Intestinal infection
ccs138 Esophageal disorders
ccs139 Gastroduodenal ulcer (except hemorrhage)
ccs140 Gastritis and duodenitis
ccs141 Other disorders of stomach and duodenum
ccs143 Abdominal hernia
ccs145 Intestinal obstruction without hernia
ccs146 Diverticulosis and diverticulitis
ccs149 Biliary tract disease
ccs151 Other liver diseases
ccs152 Pancreatic disorders (not diabetes)
ccs153 Gastrointestinal hemorrhage
ccs154 Noninfectious gastroenteritis
ccs155 Other gastrointestinal disorders
ccs157 Acute and unspecified renal failure
ccs158 Chronic kidney disease
ccs159 Urinary tract infections
ccs160 Calculus of urinary tract
ccs161 Other diseases of kidney and ureters
ccs162 Other diseases of bladder and urethra
ccs163 Genitourinary symptoms and ill-defined conditions
ccs164 Hyperplasia of prostate
ccs19 Cancer of bronchus; lung
ccs197 Skin and subcutaneous tissue infections
ccs198 Other inflammatory condition of skin
ccs199 Chronic ulcer of skin
ccs2 Septicemia (except in labor)
ccs202 Rheumatoid arthritis and related disease
ccs203 Osteoarthritis
ccs204 Other non-traumatic joint disorders
ccs205 Spondylosis; intervertebral disc disorders; other back problems
ccs206 Osteoporosis
ccs207 Pathological fracture
ccs209 Other acquired deformities
ccs211 Other connective tissue disease
ccs212 Other bone disease and musculoskeletal deformities
ccs238 Complications of surgical procedures or medical care
ccs259 Residual codes; unclassified
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ccs29 Cancer of prostate
ccs3 Bacterial infection; unspecified site
ccs4 Mycoses
ccs42 Secondary malignancies
ccs44 Neoplasms of unspecified nature or uncertain behavior
ccs47 Other and unspecified benign neoplasm
ccs48 Thyroid disorders
ccs49 Diabetes mellitus without complication
ccs50 Diabetes mellitus with complications
ccs51 Other endocrine disorders
ccs52 Nutritional deficiencies
ccs53 Disorders of lipid metabolism
ccs54 Gout and other crystal arthropathies
ccs55 Fluid and electrolyte disorders
ccs58 Other nutritional; endocrine; and metabolic disorders
ccs59 Deficiency and other anemia
ccs60 Acute posthemorrhagic anemia
ccs62 Coagulation and hemorrhagic disorders
ccs63 Diseases of white blood cells
ccs651 Anxiety disorders
ccs653 Delirium dementia and amnestic and other cognitive disorders
ccs657 Mood disorders
ccs659 Schizophrenia and other psychotic disorders
ccs660 Alcohol-related disorders
ccs661 Substance-related disorders
ccs663 Screening and history of mental health and substance abuse codes
ccs7 Viral infection
ccs79 Parkinson‘s disease
ccs81 Other hereditary and degenerative nervous system conditions
ccs82 Paralysis
ccs83 Epilepsy; convulsions
ccs87 Retinal detachments; defects; vascular occlusion; and retinopathy
ccs88 Glaucoma
ccs89 Blindness and vision defects
ccs94 Other ear and sense organ disorders
ccs95 Other nervous system disorders
ccs96 Heart valve disorders
ccs97 Peri-; endo-; and myocarditis; cardiomyopathy (except that caused by tuberculosis or sexually transmitted
disease)
ccs98 Essential hypertension
ccs99 Hypertension with complications and secondary hypertension
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B.2 Year-specific LOS and readmission HDNs
(a) 2010 (b) 2011
(c) 2012 (d) 2013
Figure B.1: Year-specific LOS and readmission HDNs
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(e) 2014 (f) 2015
(g) 2016 (h) 2017
Figure B.1: Year-specific LOS and readmission HDNs
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(i) 2018
Figure B.1: Year-specific LOS and readmission HDNs
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C.1 Rivaroxaban versus dabigatran for atrial fibrillation
Table C.1: ICD-9-CM codes for identifying eligible individuals




Dabigatran-150mg dabigatran etexilate mesylate
Rivaroxaban-20mg rivaroxaban
Exclusion (three months of history)
Received prior treatment with





A potential alternative indication for anticoagulation
Mitral valve disease
394.x-397.x, 398.9, 42.4x, V42.4, V43.3
Heart valve repair or replacement
Venous thromboembolism 451.1, 451.2, 451.81,451.9, 453.1, 453.2, 453.8, 453.9,
671.3, 671.4
Phlebitis or thrombophlebitis 451.x
Pulmonary embolism 415.1x
Joint replacement V43.60-V43.66, V43.69
* Primary or any secondary diagnosis code
113
Table C.2: Generic drug names, ICD-9-CM codes, and Medicare MCC indicators for defining
confounders
Variable Generic drug name / ICD-9-CM Code* / Medicare
MCC indicator
Medical History
Diabetes mellitus DIABETES EVER
Hypertension HYPERT EVER
CKD CHRONICKIDNEY EVER
History of bleeding (3m preceding) Intracranial bleeding 430, 431, 432; Hemoperitoneum 568.81;
Hematuria 599.7; GI hemorrhage 530.7, 531.0, 531.2, 531.4,
531.6, 532.0, 532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 533.6,
534.0, 534.2, 534.4, 534.6,569.3, 535.01, 535.11, 535.21, 535.31,
535.41, 535.51, 535.61, 535.71, 537.83, 537.84 , 562.02 ,562.03,
562.12, 562.13, 569.85, 578; Epistaxis 784.7; Hemoptysis 786.3;
Vaginal hemorrhage 623.8, 626.2; Hemarthrosis 719.1, 719.2;
NOS hemorrhage 459
Acquired HT HYPOTH EVER
No. of other CMS comorbidities
Alzheimer’s disease ANEMIA EVE
Related disorders or senile dementia ALZH DEMEN EVER
Anemia ANEMIA EVER
Asthma ASTHMA EVER
Benign prostatic hyperplasia HYPERP EVER
Cataract CATARACT EVER
COPD COPD EVER
Ischemic heart disease ISCHEMICHEART EVER




Rheumatoid arthritis or osteoarthritis RA OA EVER
Breast cancer CANCER BREAST EVER
Colorectal cancer CANCER COLORECTAL EVER
Prostate cancer CANCER PROSTATE EVER
Lung cancer CANCER LUNG EVER




Previous stroke or TIA STROKE TIA EVER
Medication Use
NSAIDs Filling a prescription for diclofenac, ibuprofen, naparofen, keto-
profen, fenoprofen, flurbiprofen, piroxicasm, meloxicam, mefe-
namic acid, or indomethacin after the index date
Antiplatelet Filling a prescription for aspirin, clopidogrel, prasugrel, dipyri-
damole, ticlopidine, or ticagrelor after the index date
* Primary or any secondary diagnosis code
MCC multiple chronical condition, CMS centers for Medicare & Medicaid services, CKD chronic kidney disease,
HT hypothyroidism, COPD chronic obstructive pulmonary disease, AMI acute myocardial infarction,
CHF congestive heart failure, TIA transient ischemic attack, NSAIDs non-steroidal anti-inflammatory drug
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Table C.3: ICD-9-CM codes used for defining study outcomes
Outcome ICD-9-CM Codes*
Primary outcome
Ischemic stroke 433, 434, 436
Other thromboembolic events Systemic embolism (444), TIA (435), Pulmonary embolism (415.1)
Major bleeding Intracranial bleeding (430, 431, 432), Hemoperitoneum (568.81), Hema-
turia (599.7), GI hemorrhage (530.7, 531.0, 531.2, 531.4, 531.6, 532.0,
532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 533.6, 534.0, 534.2, 534.4,
534.6,569.3, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61,
535.71, 537.83, 537.84 , 562.02 ,562.03, 562.12, 562.13, 569.85, 578)
All-cause mortality N/A
Secondary outcome
Any bleeding event Major bleeding; Epistaxis (784.7), Hemoptysis (786.3), Vaginal hem-
orrhage (623.8, 626.2), Hemarthrosis (719.1, 719.2), NOS hemorrhage
(459)
Acute myocardial infarction 410
* Primary or any secondary diagnosis code
Table C.4: Baseline characteristics of the study cohorts, after IPT weighting
Variables Trial 1 Trial 2 Trial 3
R D R D R D
Demographics
Age(years)
65-74 8743 (48.43) 8749 (48.47) 13384 (46.35) 13391 (46.36) 12747 (49.47) 12768 (49.53)
75-84 7314 (40.52) 7327 (40.59) 11983 (41.50) 11985 (41.49) 10467 (40.63) 10469 (40.61)
≥ 85 1995 (11.05) 1975 (10.94) 3509 (12.15) 3510 (12.15) 2551 (9.90) 2541 (9.86)
Sex (female) 8804 (48.77) 8794 (48.72) 13536 (46.87) 13540 (46.87) 12130 (47.08) 12136 (47.08)
Race
White 16460 (91.65) 16465 (91.67) 26734 (92.97) 26743 (92.96) 23531 (91.96) 23537 (91.94)
Black 727 (4.05) 725 (4.04) 1073 (3.73) 1075 (3.74) 1107 (4.33) 1112 (4.34)
Other 774 (4.31) 770 (4.29) 949 (3.30) 950 (3.30) 950 (3.71) 951 (3.72)
Medical history
Diabetes mellitus 7547 (41.81) 7552 (41.84) 12400 (42.94) 12404 (42.94) 10999 (42.69) 11026 (42.77)
Hypertension 16688 (92.44) 16686 (92.44) 26968 (93.39) 26979 (93.40) 23856 (92.59) 23880 (92.64)
CKD 4680 (25.93) 4673 (25.89) 7605 (26.34) 7608 (26.34) 7013 (27.22) 7003 (27.17)
History of bleeding 422 (2.34) 419 (2.32) 774 (2.68) 774 (2.68) 684 (2.66) 688 (2.67)
Acquired HT 5037 (27.90) 5045 (27.95) 8453 (29.28) 8458 (29.28) 7578 (29.41) 7573 (29.38)
No. of other
CMS comorbidities
0-3 4945 (27.39) 4935 (27.34) 7142 (24.73) 7144 (24.73) 6878 (26.69) 6871 (26.65)
4-6 8536 (47.29) 8543 (47.33) 14130 (48.93) 14137 (48.94) 12271 (47.63) 12303 (47.73)
≤ 7 4571 (25.32) 4571 (25.33) 7605 (26.34) 7604 (26.33) 6616 (25.68) 6604 (25.62)
Cardiovascular disease
AMI 1384 (7.66) 1372 (7.60) 2202 (7.63) 2206 (7.64) 1981 (7.69) 2007 (7.79)
CHF 8406 (46.57) 8411 (46.60) 13857 (47.99) 13856 (47.97) 11705 (45.43) 11693 (45.36)
Stroke or TIA 4040 (22.38) 4041 (22.39) 6432 (22.28) 6433 (22.27) 5775 (22.42) 5770 (22.38)
Medication use
NSAIDs 1562 (8.65) 1565 (8.67) 1967 (6.81) 1970 (6.82) 1971 (7.65) 1971 (7.65)
Antiplatelet 2050 (11.35) 2051 (11.37) 2627 (9.10) 2636 (9.13) 2692 (10.45) 2719 (10.55)
R rivaroxaban, D dabigatran, CMS centers for Medicare & Medicaid Services,CKD chronic kidney disease,
AMI acute myocardial infarction, CHF congestive heart failure, TIA transient ischemic attack, HT hypothyroidism,
NSAIDs non-steroidal anti-inflammatory drug
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Figure C.1: Histograms of the after-weighting propensity scores for trial 1
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C.2 Endovascular versus open aortic repair for abdominal aortic
aneurysms
C.2.1 ICD-9-CM codes for defining study cohort and confounders
Table C.5: ICD-9-CM codes for defining study cohort and confounders (one year of medical history)
Variable ICD-9-CM Code*
Inclusion
Ruptured abdominal aortic aneurysm 441.3
Endovascular aortic repair 39.71
Open aortic repair 38.44, 39.25, 39.52, 38.34, 38.64, 38.40, 38.60
Exclusion
Thoracic aneurysms 441.1, 441.2
Thoracoabdominal aneurysms 441.6, 441.7
Aortic dissection 441.00-441.03
Repair of the thoracic aorta 38.35, 38.45, 39.73
Visceral or renal bypass 38.46, 39.24, 39.26
Medical history
Congestive heart failure 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.91, 404.13,
404.93, 425.4, 425.5, 425.7, 425.8, 425.9, 428.0, 428.1, 428.20, 428.22,
428.30, 428.32, 428.40, 428.42, 428.9
Cardiac arrhythmia 426.0, 426.10, 426.11, 426.12, 426.13, 426.7, 426.9, 427.0, 427.1, 427.2,
427.3, 427.9, V45.0, V53.3
Valvular disease 093.2, 394, 395, 396, 397, 424, V42.2, V43.3
Coronary disease 412, 413, 414, 429.2
Diabetes 250
Hypertension 401, 402, 403, 404, 405
Chronic Obstructive Pulmonary diseases 416, 417.9, 490, 491, 492, 493, 494, 495.0, 495.1, 495.2, 495.3, 495.4,
495.5, 495.6, 495.8, 495.9, 496, 500, 501, 502, 503, 504, 505, 506.0,
506.2, 506.4, 506.9, 508.1, 508.8, 508.9
Clinically significant lower extremity vas-
cular diseases
440.22, 440.23, 440.24, 440.3, 444.22, V43.4
Renal atherosclerosis 440.1
Vascular intestine disease 557.1
Renal failure w dialysis V45.1, V56.0, V56.1, V56.2, V56.3, V56.8, 585.6, 39.95 (w/o 586)
Renal failure without dialysis 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93,
585 (w/o 585.6), 588.0
Other renal diseases 582, 583.0, 583.1, 583.2, 583.4
Kidney transplant V420
Liver disease 070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.9, 456.0, 456.1, 571,
572.1, 572.2, 572.3, 572.4, 572.8, 573.0, 573.1, 573.8, 573.9
Cerebrovascular diseases and paralysis 342, 344.1, 344.3, 344.4, 344.5, 344.9, 437.0, 438
Other neurological diseases 330, 331, 332, 333, 334.0, 334.1, 334.2, 334.4, 334.8, 335.0, 335.1, 335.2,
335.8, 335.9, 336.0, 336.2, 343, 344.0, 348.1, 348.3, 344.2, 344.6, 345,
437.3, 437.4, 437.5, 437.6, 437.7
Hyperlipidemia 272
Cancer 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154,
155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 170, 171,172, 174,
175, 176, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191,
192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203.0, 238.6
Rheumatoid arthritis 446, 701.0, 710.0, 710.1, 710.2, 710.3, 710.4, 710.8, 710.9, 711.2, 719.3,
714,720, 725, 728.5, 728.89
Prior intact AAA diagnosis 441.4, without mention 441.3
* Primary or any secondary diagnosis/procedure code
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C.2.2 Regression analysis
In “standard” clinical trial analyses as well as emulated trial analyses [131, 151], regression tech-
niques have generally been adopted. Here to complement the analysis presented in the main text,
we also conduct regression-based analysis. The overall strategy is similar to that presented in
Section 4.2.2. The first step is to estimate the propensity score using a logistic regression. The
same set of variables as presented in Table 4.4 is included. Then we conduct the IPT weighted
Cox regression analysis. Both steps can be realized using existing R functions. For inference, we
directly use the p-values generated by Cox regression. There is hence no need for bootstrap.
The estimated propensity scores are shown in Figure C.2.
In the analysis of short-term survival, the estimated coefficient of EVAR is -0.611, with a
standard error of 0.027 and a p-value less than 0.001. Other significant variables include age, hy-
pertension, chronic obstructive pulmonary diseases, and prior intact AAA diagnosis. More detailed
estimation and inference results are available from the authors. We test the proportional hazards
assumption, and the global Chi-squared test returns a p-value less than 0.001, suggesting a viola-
tion of model assumptions. We further plot the scaled Schoenfeld residuals for treatment in the left
panel of Figure C.3 and observe that the residuals are correlated with time. The plot of deviance
in the right panel of Figure C.3 also suggests a violation of model assumptions.
In the analysis of long-term survival, the estimated coefficient of EVAR is -0.317, with a standard
error of 0.002 and a p-value less than 0.001. Other significant variables include age, hypertension,
chronic obstructive pulmonary diseases, and prior intact AAA diagnosis. The global Chi-squared
test returns a p-value less than 0.001, which, along with Figure C.4, suggests that the Cox model
assumptions are not satisfied.
Overall, we present the regression-based results for completeness but note that, with the viola-
tions of model assumptions, their results should not be utilized.
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Figure C.2: Distribution of propensity score using logistic regression
Figure C.3: Analysis of short-term survival using Cox regression (left: Scaled Schoenfeld residuals
for treatment; right: Deviance residuals)
Figure C.4: Analysis of long-term survival using Cox regression (left: Scaled Schoenfeld residuals
for treatment; right: Deviance residuals)
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